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Abstract 
 
Structural characterisation of the interaction between RBBP6 and the multifunctional 
protein YB-1 
Victor Muleya 
M.Sc. (Biotechnology) thesis, Department of Biotechnology, Faculty of Natural Sciences, 
University of the Western Cape. 
 
Retinoblastoma binding protein 6 (RBBP6) is a 250 kDa RING finger-containing protein whose 
function is known to be mediated through interaction with other proteins. RBBP6 plays a role in 
the regulation of the tumour suppressor protein p53 and is also thought to be involved in mRNA 
splicing although its role has yet to be characterised. A recent study utilising a yeast 2-hybrid 
screen identified the cancer-associated protein known as YB-1 as an interacting partner of 
RBBP6, and showed that RBBP6 ubiquitinates YB-1, leading to its degradation in the 
proteasome. 
 
Human Y-box binding protein 1 (YB-1) is member of the cold-shock domain family of proteins, 
which regulates a number of growth related genes through both transcriptional and translational 
mechanisms. YB-1 is a cell-survival factor whose expression is increased in proliferating normal 
and cancer cells. It also protects cells against p53-mediated apoptosis by repressing the p53-
promoter and down-regulating endogenous p53. The interaction between RBBP6 and YB-1 
involves the RING finger-like domain of RBBP6 and the C-terminal 62 amino acids of YB-1. 
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As a means of further localising the interaction, truncated fragments derived from the C-terminal 
region of YB-1, were tested for their interaction with the RING finger domain of RBBP6 using 
three different assays: a directed yeast 2-hybrid assay, co-immunoprecipitation and NMR 
chemical shift perturbation analysis. Our results suggest that the entire 62 amino acid region at 
the C-terminal domain of YB-1 may be involved in the interaction with RBBP6. Using chemical 
shift perturbation analysis, this study provides an indication of where YB-1 binds to the RING 
finger. This represents the first step towards the design of therapeutics aimed at modulating the 
interaction between RBBP6 and YB-1 as a means of targeting the oncogenic effects of YB-1. 
 
In order to identify E2 enzymes involved in the ubiquitination of YB-1, we examined the 
efficiencies of selected E2s in an in vitro ubiquitination assay. UbcH5c and UbcH7 were both 
found to catalyse the ubiquitination of YB-1 in conjuction with RBBP6, whereas Ubc13 was not. 
Finally, we show using NMR that two single-point mutations of the RING finger-like domain are 
sufficient to abolish homodimerisation of the domain. These will be used in future studies to 
investigate the requirement for homodimerisation on the ubiquitination activity of RBBP6. 
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Chapter 1: General introduction  
1.1 Introduction 
Proteins have a propensity to specifically bind to other proteins as a means of mediating cellular 
function. These protein associations are of central importance for virtually every process in a 
living cell, including DNA replication, transcription, mRNA translation, protein degradation and 
signal transduction, to mention only a few. Many of these cellular processes are enacted by 
networks of interacting multi-protein complexes. The protein components that constitute these 
functional assemblies often interact in a transient and reversible manner and their arrangement is 
rapidly assembled and disassembled in preparation for the next required activity (Hanlon et al., 
2010).  
 
A good example of a protein which exerts its function through protein-protein interaction is that 
of X-linked Inhibitor of Apoptosis Protein (XIAP). Through its Baculoviral IAP Repeat (BIR) 
domain, XIAP interacts with executioner caspases thereby inhibiting their function and 
preventing apoptosis (Abhari et al., 2010). Protein-protein associations are also important in 
receptor-ligand interactions on cell surfaces, converting an extracellular signal into a response 
through a relay of protein-protein interactions. For example, extracellular Notch-3 receptor 
domains on the surface of mesangial and immune cells interact with a protein known as Y-box 
binding protein 1 (YB-1) upon cytokine challenge. This interaction activates Notch-3 signalling, 
resulting in nuclear translocation of the Notch-3 intracellular domain and subsequent up-
regulation of Notch target genes (Rauen et al., 2009). Aberrations in such intricate protein 
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associations often lead to disease states such as cancer. Deciphering these protein-protein 
interactions is crucial in the understanding of cellular processes and pharmaceutical 
development.  
 
Retinoblastoma binding protein 6 (RBBP6) is a 250 kDa multi-functional human protein whose 
functions appear to be mediated predominantly through protein-protein interactions. RBBP6 
plays an as-yet uncharacterised role in the splicing and 3′-end processing of messenger RNA 
(mRNA): its yeast homologue, Mpe1, forms part of the Cleavage and Polyadenylation Factor 
(CPF) and this human protein forms part of the 3′-end processing complex (Shi et al., 2009). It 
has been shown to interact with mRNA splicing-associated protein SmG (Pugh and Chibi, 
unpublished data). RBBP6 interacts directly with the tumour suppressor p53 and facilitates its 
ubiquitination by Murine Double Minute 2 (MDM-2) (Li et al., 2007). In addition, RBBP6 also 
interacts with another prototypical tumour suppressor protein, the Retinoblastoma gene product 
(pRB), underscoring its significance in tumourigenesis (Simons et al., 1997). A recent study has 
employed a novel systems genetics approach, to implicate  RBBP6 in the regulation of 
transcription, in particular estrogen-dependant transcription (Peidis et al., 2010). 
 
RBBP6 is also involved in the ubiquitination of certain protein substrates due to the presence of a 
RING finger domain that confers E3 ubiquitin-ligase activity. In a recent study employing the 
yeast 2-hybrid technique, RBBP6 was identified as an interaction partner of the multifunctional 
protein Y-box binding protein 1 (YB-1) (Chibi et al., 2008). This interaction was mapped to a 62 
amino acid region at the C-terminus of YB-1. The RBBP6/YB-1 interaction was shown to lead to 
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the ubiquitination of YB-1, consequently resulting in the proteolytic degradation of YB-1 in a 
proteasome-dependant manner (Chibi et al., 2008). 
 
YB-1 is a prototypical member of the cold shock domain family of proteins that are known to be 
involved in both translational and transcriptional gene regulation (Lu et al., 2005). By and large, 
YB-1 can be broadly characterised as a cell survival factor that up-regulates a number of growth-
promoting genes and its expression is closely correlated with cell proliferation. YB-1 expression 
has been shown to be up-regulated in proliferating human adult tissues and in a number of 
human carcinomas (Matsumoto et al., 2005). Consistent with this observation, YB-1 over-
expression has been linked to adverse clinicopathological effects in most human cancers. YB-1 
has also been demonstrated to be anti-apoptotic through its ability to repress the transcription of 
the tumour suppressor protein p53, thereby enabling tumourigenic cells to survive (Lasham et 
al., 2003; Homer et al., 2005). As a result of its overwhelming significance in tumourigenecity, 
YB-1 is increasingly being identified as an important marker of prognosis in clinical oncology 
(Dahl et al., 2009; Huang et al., 2005; Kashihara et al., 2009). 
 
The principal aim of this study is to understand the structural basis of the RBBP6/YB-1 
interaction and to gain more insight into the mechanism involved in YB-1 ubiquitination. This 
chapter reviews the structural organisation and the pleiotropic functions of both RBBP6 and YB-
1. Since the functions of these proteins appear to be mediated by protein-protein interactions, this 
chapter also reviews the techniques  available for studying protein-protein interactions, with the 
main focus on biomolecular NMR, complex immunoprecipitation (Co-IP) and the yeast 2-hybrid 
(Y2H) technique.  
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1.2 Y-Box Binding Protein Family 
Y-Box binding proteins are multifunctional proteins belonging to the cold shock domain family, 
a highly conserved protein family found in plants, bacteria and animals (Kohno et al., 2003). 
They were originally identified as DNA-binding proteins that are capable of interacting with the 
cis-acting DNA regulatory element known as the Y-box element (inverted CCAAT-box or 
GGTTA)(Didier et al., 1988). Due to their DNA-binding properties, Y-box proteins control the 
transcription and translation of a number of genes.  
 
Apart from their inherent ability to interact with DNA, Y-box proteins have also been shown to 
interact with a myriad of cellular and viral proteins that are involved in a number of cellular 
processes. Y-box proteins exhibit functional pluripotency as they are involved in a diverse range 
of biological functions including transcriptional modulation  of a wide array of genes, chromatin 
modification, translational masking of mRNA, participation in eukaryotic redox signalling 
pathways, RNA chaperoning, cell cycle control and stress response (Ruzanov et al., 1999; 
Uchiumi et al., 2006; Khandelwal et al., 2009).  
 
Y-box proteins share a common domain arrangement across a wide range of taxa, consisting of 
an N-terminal domain, the evolutionarily conserved Cold Shock Domain (CSD) and a C-terminal 
tail domain. The N-terminal domain of most Y-box proteins is an alanine/proline-rich domain 
which has been shown to confer Y-box proteins in Caenorhabditis tentans, human and rabbit an 
ability to bind to actin filaments (Soop et al., 2003; Khandelwal et al., 2009). However, current 
understanding of the functional role of the N-terminal domain in non-human Y-box proteins is 
limited. 
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The CSD is a highly stable domain which confers nucleic acid-binding properties to the Y-box 
proteins. It is noteworthy that prokaryotes lack the CSD, but they contain a domain similar to the 
CSD in the form of Cold Shock Proteins (CSPs). Well documented CSPs are those from the 
mesophilic bacterium Escherichia coli, which have been implicated to play a role in the cold 
shock response during the cold acclimation phase (Phadtare, 2004); for example CspA functions 
as an RNA chaperone that facilitates translation at low temperature by blocking the formation of 
secondary RNA structures in mRNA (Inouye et al., 2004). The CSD-containing proteins were 
initially characterised for prokaryotes and higher animals but are increasingly being 
characterised in both lower animals and plants as well. CSD proteins have been well-documented 
in Arabidopsis Thaliana, tobacco, Chlamydomonas reinhardtii, Ceratopteris richardii and wheat 
(Karlson et al., 2002; Karlson et al., 2003; Kim et al., 2007). As with prokaryotic CSPs, CSD 
proteins in higher plants have been shown to function as RNA chaperones capable of 
destabilising RNA secondary structure and  have also been demonstrated to regulate translation 
under low temperatures (Nakaminami et al., 2006). 
 
The structure of the C-terminal domain of Y-box proteins varies significantly across taxa. These 
structural differences are shown in Fig 1.1. In vertebrate Y-box binding proteins, the C-terminal 
domain consists of alternating clusters of basic and acidic amino acids (B/A repeats), each about 
30 amino acids in length. This feature is also found in proteins that bind to ribonucleoprotein 
complexes for shuttling between the nucleus and the cytoplasm (Wu et al., 2007; Shu-Nu et al., 
2000). Within invertebrate Y-box proteins there is significant variation in their C-terminal 
domains. In Drosophila melanogaster and in the marine invertebrate Aplysia californica the tail 
domain lacks acidic amino acids and contains multiple RNA-binding RGG repeats (Takiya et al., 
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2004). In Caenorhabditis elegans the C-terminal domain contains zinc fingers (Worringer et al., 
2007) and in Schistosoma mansoni it contains a fibroin-like -sandwich structure due to the 
presence of tandem repeats of arginine and glycine residues (Valadao et al., 2002). These tandem 
repeats of arginine and glycine residues are predicted to project towards a common surface, 
providing a second site for nucleic acid binding. The presence of distinct nucleic acid binding 
sites within a protein is often associated with regulatory functions, as it allows the protein to 
regulate a number of different genes. These structural alterations in the C-terminal domain may 
have been necessary for the evolution from poikilotherms (organisms whose internal temperature 
varies along with that of the ambient environmental temperature) to homiotherms (organisms 
that maintain thermal homeostasis) and could be responsible for conferring the pleiotropic 
functions exhibited by Y-box binding proteins (Kohno et al., 2003). 
 
 
1.3 Human Y-box binding protein-1 (YB-1) 
 Human Y-box binding protein-1, also known as dbpB or p50, is the most extensively studied of 
the Y-box proteins. It is a 43 kDa protein which was initially identified as a transcription factor 
that specifically recognises the Y-box promoter element (inverted CCAAT or GGTTA) in a 
variety of different genes (Didier et al., 1988). The YB-1 gene comprises 8 exons spanning 19 kb 
of genomic DNA, located on chromosome 1p34 (Kuwano et al., 2004). The mRNA is 
approximately 1.5 kb long and encodes a 324 amino acid protein. 
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Fig. 1.1 Y-box proteins from different organisms. The Y-box proteins are aligned at their CSDs (the 
blue region) and the different features on the C-terminal tail domains are indicated. The C-terminal tail 
domains differ significantly in their sequence organisation. Adapted from(Matsumoto et al., 1998).  
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The structure of YB-1 is characteristic of Y-box proteins, consisting an N-terminal 
alanine/proline-rich domain (AP), cold-shock domain (CSD) in its central part and a C-terminal 
tail domain (Fig. 1.2). The C-terminal tail domain is composed of four alternating clusters of 
negatively and positively charged amino acids and is the major domain that mediates protein-
protein interactions involving YB-1 (Selivanova et al., 2010). The N-terminal AP domain of YB-
1 is known to associate with actin microfilaments, presumably contributing to mRNA 
localization (Chernov et al., 2008). YB-1 also contains an ATP-binding motif at its N-terminus 
between residues 28-58 which is thought to play a major role in the strand separation activities 
involving YB-1 (Guay et al., 2008; Gaudreault et al., 2004). The N-terminal domain also 
mediates YB-1’s cell proliferation- promoting function by sequestering cyclin D1 in the 
cytoplasm (Khandelwal et al., 2009). 
 
 
1.4 Functions of YB-1 
YB-1 shuttles between the nucleus and the cytoplasm, exhibiting different functions depending 
on its cellular localization. The mechanism of YB-1 translocation to the nucleus is a poorly 
understood phenomenon and there are several conflicting hypotheses (Sorokin et al., 2007; 
Cohen et al., 2010; Basaki et al., 2007). When in the nucleus, YB-1 controls the transcription of 
a number of genes involved in cell proliferation and differentiation (En-Nia et al., 2005; Jurchott 
et al., 2003) whereas in the cytoplasm it plays crucial functions in RNA metabolism and interacts 
with tubulin and microtubules, promoting microtubule assembly (Chernov et al., 2008).  
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Fig. 1.2 Domain organisation in YB-1. (A) Cartoon representation of the 3D structure of the CSD from 
human YB-1 (PDB: 1H95). The CSD is a stable domain containing a 5-stranded anti-parallel β-sheet. The 
β-strands are shown in red arrows, while the connecting loops are shown in green. Figure created using 
Swiss PDB viewer. Adapted from (Kloks et al., 2002). (B) Schematic representation of the structure of 
YB-1 showing the three constitutive domains and their amino acid boundaries: the alanine/proline-rich 
(AP) N-terminal domain spanning from 1 to 55, the cold-shock domain (CSD) from 55 to128 and the C-
terminal tail domain (CTD) from 128 to 324. ++ and -- indicate alternating clusters of basic and acidic 
amino acids, respectively. Adapted from (Sorokin et al., 2007). 
A 
B 
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1.4.1 Transcriptional regulation 
The number of genes in the cell regulated by YB-1 is very large.  Among others, these genes 
include histones, dihydrofolate reductase, thymidine kinase and thymidine synthase, Proliferating 
Cell Nuclear Antigen (PCNA), topoisomerase IIα, and DNA Polymerase α (DPA) (En-Nia et al., 
2005). Most YB-1 responsive genes are growth-promoting and many of them are involved in 
DNA replication, including Epidermal Growth Factor Receptor (EGFR), PCNA, human growth 
factor receptor (HER)-2, cyclin A, cyclin B1 and DPA, all of which are regulated by YB-1 in a 
Y-box dependent manner (Evdokimova et al., 2006a; Kloks et al., 2002). The promoter regions 
of most YB-1 responsive genes contain a Y-box sequence motif along their sequences 
(CTGATTGG), also known as the inverted CCAAT box. YB-1 recognizes and binds to this Y-
box element, thereby activating or repressing expression of these genes. 
 
For example, the Y-box is present in the promoter region of the Multidrug Resistance 1 (MDR1) 
gene which codes for P-glycoprotein, an adenosine triphosphate-dependent (ATP-dependent) 
efflux pump that reduces drug accumulation in chemo-resistant cells (Choi, 2005; Wang et al., 
2006). YB-1 activates the MDR1 gene, leading to the overexpression of the P-glycoprotein gene 
(Saji et al., 2003; Vaiman et al., 2006). It has also been reported that nuclear expression of YB-1 
protein correlates with P-glycoprotein expression in human breast carcinomas (Huang et al., 
2004; Wang et al., 2006).   
  
The expression of two genes, EGFR and HER-2, both of which promote tumour growth, has also 
been shown to be regulated by YB-1 (Stratford et al., 2007; Wu et al., 2006). Wu and co-workers 
demonstrated that the disruption of YB-1 resulted in the suppression of levels of EGFR and 
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HER-2, the products of the EGFR and HER-2 genes respectively (Wu et al., 2006). Cyclin A and 
cyclin B1 genes, both of which are crucial for cell cycle progression, have also been 
demonstrated to be transcriptionally activated by the nuclear accumulation of YB-1 (Jurchott et 
al., 2003). Both contain a CCAAT-box within their promoters, to which YB-1 has been shown to 
bind (En-Nia et al., 2005; Saji et al., 2003). Cyclin A is required for the onset of DNA 
replication in the G2-S phase transition of the cell cycle and independently induces DNA 
replication, but executes this role synergistically with cyclin E (Tsang et al., 2007). 
Overexpression of cyclin A affects cell cycle progression and leads to accelerated entry into the 
S phase which supports the multiplication of tumorigenic cells. 
 
1.4.2 Translational control and mRNA metabolism 
YB-1 is a non-specific RNA-binding protein that is involved in the regulation of a broad range of 
mRNA metabolic processes including transcription, splicing, and translation and even mRNA 
stability. The RNA-binding ability of YB-1 is conferred by the RNA-binding motifs present in 
the CSD of YB-1. YB-1 has been shown to inhibit mRNA translation in both cap-dependent and 
cap-independent mechanisms. Consistent with its inhibitory role in translation,YB-1 is a major 
constituent of Messenger Ribonucleoprotein Particles (mRNPs), cytoplasmic complexes which 
are responsible for the storage of mRNA in a translationally inactive (silent) state (Skabkin et al., 
2004). While in this complex, YB-1 binds in close proximity to the mRNA cap structure and is 
able to displace the initiation factors, Eukaryotic translation Initiation Factor 4E (eIF4E) and 
eIF4G from the transcript, thereby causing mRNA translational silencing (Nekrasov et al., 2003).  
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The cap-dependent mechanism of translational silencing by YB-1 has been well documented. 
The association of YB-1 with the capped 5′-terminus of the mRNA is regulated via 
phosphorylation by the serine/threonine protein kinase Akt (Evdokimova et al., 2006b). 
Evdokimova and co-workers showed that Akt-phosphorylated YB-1 failed to inhibit cap-
dependent translation of a reporter mRNA. YB-1 has recently been implicated in the regulation 
of mRNA translation using a novel cap-independent mechanism (Mouneimne et al., 2009). This 
has been reported to occur when epithelial cancer cells transform to mesenchymal cells during 
the invasive phase of metastasis in a process known as Epithelial-to-Mesenchymal Transition 
(EMT). YB-1 regulates transcription of many EMT-related proteins in a cap-independent manner 
(Evdokimova et al., 2009). 
 
1.4.3. Stress response 
Several studies have demonstrated that YB1 is directly involved in the cellular response to 
genotoxic stress. YB-1 contains a non-canonical Nuclear Localisation Signal (NLS)  at its C-
terminus as well as a Cytoplasmic Retention Signal (CRS) (Bader et al., 2005; Sorokin et al., 
2005). Until very recently, the nuclear export of YB-1 was believed to be dependent on 
proteolytic cleavage of the C-terminal 105-amino-acids of YB-1 which contain the cytoplasmic 
retention signal (Sorokin et al., 2005). This proteolytic cleavage was thought to be induced by 
genotoxic stimuli. However a recent study has shown that the nuclear export of YB-1 is 
independent of proteolytic cleavage by the 20S proteasome and that the full length YB-1 protein 
is present in the nucleus (Cohen et al., 2010). The relationship between these sets of observations 
is not clear but there is a consensus among researchers that import of YB-1 into the nucleus can 
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be induced by stress and genotoxic stimuli such as UV radiation, hyperthermia, and anticancer 
agents.  
 
The nucleocytoplasmic transport of YB-1 is thought to occur through the Nuclear Pore Complex 
(NPC) – a large protein complex spanning the nuclear envelope (Serokin et al., 2007). The 
nuclear transport of YB-1 is mediated by a family of transport receptors known as karyopherins, 
which, bind their cargoes via recognition of an NLS. Once in the nucleus, nuclear YB-1 protects 
cells from genotoxic insults associated with exposure to DNA-damaging agents like UV 
radiation and anticancer drugs. It preferentially binds to the cross-linked regions of structurally 
altered DNA promoting the re-annealing of damaged DNA (Skabkin et al., 2001; Sorokin et al., 
2005). 
 
1.4.4 DNA repair 
YB-1 plays a role in maintaining genome stability through its interaction with DNA repair 
proteins. In vitro binding studies have demonstrated that YB-1 binds to several DNA repair 
proteins including MutS Homolog 2 (MSH2), DNA polymerase , ku80 and the Werner 
syndrome protein WRN (Gaudreault et al., 2004). Apart from its ability to repair nuclear DNA, 
YB-1 has recently been implicated in the repair of mitochondrial DNA (de Souza-Pinto et al., 
2009). de Souza-Pinto and co-workers demonstrated that YB-1 participates in the mitochondrial 
mismatch repair mechanism and they were able to show that depletion of YB-1 resulted in an 
increased rate of mitochondrial DNA mutagenesis. 
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YB-1 exhibits both intrinsic endonuclease and 3′-5′ exonuclease activity on double stranded 
DNA but has been shown to bind preferentially to single-stranded nucleic acids (Gaudreault et 
al., 2004). In addition, YB-1 is a potent enhancer of the nucleotide excision activity of the base-
specific DNA glycosylase known as NEIL2 (Nei-Like-2), stimulating its activity 7-fold (Das et 
al., 2007). NEIL2-initiated base excision activity is significantly reduced in YB-1-depleted cells, 
suggesting that YB-1 performs a regulatory role in NEIL2-mediated repair under oxidative 
stress. This substantial body of evidence espouses the participation of YB-1 in the cell’s robust 
base excision repair mechanism.  
 
1.4.5 Other functions of YB-1  
Apart from regulating cellular functions such as transcription, RNA metabolism and DNA repair, 
YB-1 has been reported to be involved in numerous other cellular processes. Pathogenic viruses 
use host derived YB-1 protein to trans-activate transcription from viral promoters in infected 
cells. YB-1 facilitates adenoviral replication and the release of viral particles from infected cells 
(Glockzin et al., 2006). Furthermore, YB-1 has been shown to inhibit the ability of p53 to cause 
cell death by preventing transactivation of pro-apoptotic genes (Homer et al., 2005). 
 
Intercellular functions of YB-1 have been well-studied, and it is only recently that extracellular 
functions of YB-1 have come to light. Upon cytokine challenge, which usually occurs under 
inflammatory conditions, mesangial and immune cells both secrete YB-1 (Frye et al., 2009). 
Extracellular YB-1 has been shown to increase DNA synthesis, proliferation and migration 
suggesting that it exerts mitogenic as well as promigratory effects in inflammation. In another 
elegant study, extracellular YB-1 was shown to associate with outer cell membrane components 
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and interact with extracellular Notch-3 receptor domains on the cell surface of mesangial and 
immune cells (Rauen et al., 2009). The interaction of YB-1 with Notch-3 receptors activates 
intercellular Notch-3 signalling and the transcription of Notch responsive genes. 
 
1.4.6 Clinical significance of YB-1 
YB-1 plays a crucial role in cellular resistance to cancer therapeutic agents, whose mechanism of 
action is largely dependent on destabilisation of cellular DNA. Since YB-1 is involved in DNA 
repair systems, it poses a threat to the success of DNA-damaging anticancer agents like 
chemotherapeutic drugs and UV irradiation (Fujita et al., 2005).  
 
YB-1 also promotes resistance by upregulating the removal of chemotherapeutic agents from the 
cell (Vaiman et al., 2006). YB-1 activates the MDR1 gene which encodes P-glycoprotein which 
is overexpressed in various human tumors after chemotherapy. P-glycoprotein is an ATP-
dependant efflux pump that flushes out xenobiotic drugs from cells. Most of these xenobiotic 
compounds are anti cancer drugs which, when flushed out of the cell, fail to exert their 
therapeutic efficacy. As a result, drug resistance is conferred to cancerous cells.  
 
It has been demonstrated that YB-1 overexpression is closely associated with unfavourable 
clinical outcomes in most human carcinomas (Kuwano et al., 2004). The level of nuclear 
expression of YB-1 is predictive of drug resistance and patient survival in a variety of human 
cancers. In predictive oncology, YB-1 has of late replaced conventional prognostic markers of 
breast cancer like the EGFR and HER-2 (Dahl et al., 2009; Huang et al., 2004; Kashihara et al., 
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2009). In molecular diagnosis of breast cancer, YB-1 is used as a predictor of tumour 
aggressiveness, virulence and resistance to chemotherapeutic drugs (Habibi et al., 2008). 
 
For cancerous cells to metastasise, they first need to undergo the Epithelial-to-Mesenchymal 
Transition (EMT). YB-1 promotes the transcription of various EMT promoting factors, including 
Snail 1 and Twist (Evdokimova et al., 2009; Mouneimne et al., 2009). Furthermore, YB-1 is 
believed to promote metastasis of tumours by enhancing the transcription of gelatinase A, a 
matrix metalloproteinase that facilitates cell migration (Mertens et al., 2002). More recent 
studies have also shown that extracellular YB-1 may be capable of exerting promigratory effects 
on cells (Frye et al., 2009). These observations have adverse clinical implications as they point to 
the promotion of tumour metastasis by YB-1.  
 
Since YB-1 activates growth-promoting genes and encourages tumour metastasis, it is hardly 
surprising that YB-1 expression is significantly correlated with tumour size, degree of invasion, 
lymph node metastasis and poor prognosis in lung cancer and synovial sarcoma (reviewed in 
(Fujii et al., 2008). YB-1 also contributes to breast tumour aggressiveness, especially in invasive 
ductal breast cancer, as a result of the induction of the epidermal growth factor EGF receptor 
pathway (Berquin et al., 2005). YB-1 levels have also been found to be up-regulated during 
prostate cancer progression (Gimenez-Bonafe et al., 2004).  
 
Taken together these observations have shown YB-1 to be highly correlated with adverse 
clinicopathological effects in many human carcinomas. Many studies have proposed targeting of 
YB-1 as a means of containing cancer. However it has also been pointed out that direct targeting 
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of YB-1 might prove to be futile or even counterproductive since YB-1 has been shown to be an 
important factor in keeping cells dormant after they metastasize (Mouneimne et al., 2009). 
 
1.4.7 YB-1 in protein-protein interactions 
YB-1 performs most of its physiological functions through protein-protein interactions and it 
interacts with a number of cellular and viral proteins that are involved in various cellular 
processes. YB-1 exerts its pro-tumourigenic effects by suppressing the transcription of pro-
apoptotic genes through its interaction with the tumour suppressor protein p53 (Homer et al., 
2005). Recently, another modular protein known as Retinoblastoma Binding Protein 6 (RBBP6) 
has been shown to interact with YB-1 (Chibi et al., 2008). The interaction is believed to occur 
through the RING finger domain of RBBP6 and the C-terminal domain of YB-1. In vivo studies 
by Chibi and co-workers have demonstrated that this interaction is crucial for the ubiquitination 
and subsequent degradation of YB-1 by the 26S proteasome (Chibi et al., 2008). 
 
 
1.5 Retinoblastoma binding protein 6 (RBBP6) 
Retinoblastoma binding protein 6 is a 250 kDa human protein that was initially shown to bind to 
the retinoblastoma gene product, pRB, and accordingly designated as RBBP6 (Sakai et al., 
1995). Its significance in cancer is highlighted by its interaction with both of the prototypical 
tumour suppressor proteins, p53 and pRB (Li et al., 2007; Simons et al., 1997). While the 
physiological relevance of the RBBP6/pRB interaction remains unclear, RBBP6 has been shown 
to negatively regulate p53, interfering with p53’s binding to DNA. RBBP6 has been reported to 
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play a crucial role in the ubiquitination of p53 by MDM-2. Recent studies have shown human 
RBBP6 to play significant roles in transcription and mRNA editing (Peidis et al., 2010; Pugh et 
al., 2006; Shi et al., 2009).  
 
The domain structure of human RBBP6 is shown schematically in Fig. 1.3. RBBP6-like proteins 
are present in all eukaryotic genomes for which sequence data is available, but have not been 
found in prokaryotes. The first 3 domains - DWNN, Zinc knuckle and RING finger - are well 
conserved across all eukaryotes. However the C-terminal region is poorly conserved with few 
conserved domains being identified so far. At the N-terminus of all RBBP6 orthologues is the 
DWNN domain which adopts a ubiquitin-like fold (Pugh et al., 2006). Analysis of cDNA data 
shows that the DWNN domain is only expressed as an independent splicing isoform in 
vertebrates. There is a di-glycine peptide in the DWNN domain, which resembles the conserved 
di-glycine motif found at position 75 and 76 of ubiquitin which is essential for conjugation of 
ubiquitin to other proteins. The presence of the di-glycine motif in the DWNN domain has led to 
the suggestion that the DWNN domain may be covalently linked to proteins in the same manner 
as ubiquitin (Pugh et al., 2006). 
 
Another functionally relevant domain in human RBBP6 is the RING (Really Interesting New 
Gene) finger domain (Fig.1.4). The RING motif consists of a series of eight conserved cysteines 
and/or histidines, which bind two Zn
2+
 ions is a cross-braced configuration. However, sequence 
alignments indicate that the RBBP6 RING finger may also be classified as a member of the U-
box family of domains which adopt the same structure as RING fingers but do not require Zn
2+
 
ions to fold. The presence of the RING finger domain in RBBP6 confers E3-ubiqutin ligase 
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activity to RBBP6, implicating this protein in the ubiquitination and subsequent degradation of 
substrate proteins in a proteasome-dependent manner (Chibi et al., 2008). The structure of the 
RING finger like-domain has recently been determined using NMR spectroscopy and shown to 
adopt a homodimeric configuration very similar to that found in U-boxes (Pugh and Kappo, 
unpublished data). 
 
In addition to the DWNN domain and the RING finger domain, human RBBP6 contains a zinc 
knuckle domain that is thought to confer mRNA-binding activity to proteins ((Vo et al., 2001) 
and a serine/arginine rich domain (SR domain) that  is commonly found in splicing factors. Both 
of these are likely to play roles in the mRNA-processing functions of RBBP6, although the 
precise mechanisms remain to be discovered. Finally, human RBBP6 contains regions identified 
as interacting with p53 and pRb. These extra protein modules in human RBBP6 are thought to 
have been acquired later during evolution and are believed to confer new functionalities not 
required in lower eukaryotes, such as tumour suppression and apoptosis. 
 
1.5.1 RBBP6 in cell development and tumourigenesis 
The RBBP6 homologue in mice, known as p53-associated cellular protein-testes derived 
(PACT), interacts with the tumor suppressor protein p53 (Li et al., 2007). Li and co-workers 
have demonstrated that the PACT/p53 interaction negatively regulates p53 by increasing the 
ubiquitination and resultant proteasomal degradation of p53 by MDM-2. Since p53 plays a 
pivotal role in driving the process of programmed cell death, down regulation of p53 as a result 
of the PACT/p53 interaction has considerable implications in tumourigenesis. Studies on the 
functions of PACT using PACT knock-out mice revealed that disruption of PACT leads to early  
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Fig. 1.3 Illustration of the domain organisation in human RBBP6. The RBBP6 protein is a modular 
protein that consists of an N-terminal DWNN domain, a Zinc knuckle, a RING finger domain, SR 
domain, Rb-binding domain, p53-binding domain and a nuclear localisation signal at its C-terminal end. 
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Fig. 1.4 A cartoon representation of the homodimeric structure of the RING finger-like domain of 
human RBBP6. The picture shows the superimposed ribbon and space-filling models of the 
homodimeric RING finger domain. Each monomer is stabilised by two zinc ions (not shown in the above 
picture), and consists of a three-stranded anti-parallel B-sheet (shown as green arrows) and two alpha 
helices (green coils), linked by loops. Adapted from Pugh et al., unpublished data. 
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embryonic death accompanied by widespread apoptosis (Li et al., 2007). Taken together, these 
findings suggest that PACT is anti-apoptotic in mice and that it is essential for development. On 
the other hand, studies done on human MCF breast cancer cells suggest that RBBP6 promotes 
apoptosis (Gao et al., 2003; Gao et al., 2002). 
 
RBBP6 expression has been shown to be up regulated in oesophageal cancer (Yoshitake et al., 
2004). Yoshitake and co-workers demonstrated that RBBP6 promotes the proliferation of 
oesophageal cancer cells and that antibodies against RBBP6 can be successfully used in 
immunotherapy against oesophageal cancer, leading to decreases in tumour size.  
 
1.5.2 RBBP6 in mRNA processing 
Until recently the evidence for the involvement of RBBP6 in mRNA 3′-end processing and 
splicing was based on the presence of an SR domain, commonly found in splicing proteins, and 
the involvement of the yeast orthologue in the cleavage and polyadenylation factor (CPF) (Vo et 
al., 2001; Shi et al., 2009). Recently, RBBP6 has been shown to be a member of the human 3′-
end processing complex (Shi et al., 2009). The human pre-mRNA 3`-end processing complex 
contains approximately 85 proteins which are intricately linked to other cellular events. Shi and 
co-workers were the first to successfully isolate and purify a functional human pre-mRNA 
processing complex which they then subjected to mass spectrometry to identify the component 
proteins. Analysis of the protein composition of the human pre-mRNA processing revealed that 
RBBP6 is a component of the polyadenylation machinery. 
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Although it has yet to be directly tested for its role in pre-mRNA processing, it is likely that 
RBBP6, just like its yeast homologue Mpe1, functions in pre-mRNA processing (Vo et al., 
2001). Using the tandem affinity purification, Mpe1 was shown to be an integral component of 
the cleavage and polyadenylation factor (CPF) complex.  The CPF complex functionally 
cooperates with the poly(A) binding protein, Pab1p, and  cleavage factor I in mRNA cleavage 
and polyadenylation (Vo et al., 2001). Stable CPF devoid of Mpe1 failed to specifically cleave 
and polyadenylate mRNA, suggesting that Mpe1 is strictly required for CPF-mediated RNA 
processing.   
 
Since RBBP6 interacts with p53 and pRb, it has been speculated that RBBP6 may link mRNA 
3`-end formation to pRb/p53 pathways and tumourigenesis (Shi et al., 2009). Furthermore, using 
the yeast 2-hybrid technique, RBBP6 has recently been shown to interact with Small Nuclear 
Ribonucleoprotein G (snRPG) through its DWNN domain (Pugh, et. al., unpublished data), 
which is a crucial component of the RNA processing machinery in the cell. Taken together, these 
observations substantiate the involvement of RBBP6 in pathways involved in mRNA processing. 
 
1.5.3 Turnover of proteins 
Human RBBP6 has intrinsic E3 ubiquitin ligase activity due to the presence of the RING finger 
domain in its structure (Chibi et al., 2008). RBBP6 has been shown to ubiquitinate YB-1 both in 
vitro and in vivo, leading to the suppression of YB-1 levels in a proteasome-dependant manner. 
RBBP6 has also been shown to ubiquitinate the methyl-binding transcriptional repressor 
zBTB38 (Zinc finger and BTB domain containing 38) (Chibi and Pugh, unpublished data) and it 
is possible that other substrates remain to be identified 
 
 
 
 
24 
 
In addition to E3 ligase activity, a report from Li and co-workers suggests that RBBP6 also has 
E4 ligase activity (Li et al., 2007). Li and co-workers showed that although RBBP6 was not 
itself responsible for ubiquitination of p53, it was nevertheless required for ubiquitination of p53 
by MDM-2. They suggested that RBBP6 may play the role of a molecular scaffold, recruiting 
p53 and MDM-2 and thereby facilitating their interaction. 
 
 
1.6 Ubiquitination 
Ubiquitination is a highly specific, energy-dependant degradation process that is achieved 
through the attachment of one or more ubiquitin moieties to a target protein (Fig.1.5). Once 
tagged with ubiquitin, the target molecules are then degraded in the proteasome, a barrel-shaped 
protein complex, where proteins are disassembled by proteases. Ubiquitination is a concerted 
action of three different enzymes: ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme 
E2, and substrate-specific ubiquitin-protein ligase E3 (Kerscher et al., 2006). It is thought that 
additional conjugation factors known as E4 ligases may also be required for polyubiqutination of 
protein substrates. However, although E4 ligases have been described in the ubiquitination 
mechanisms of a few yeast and human proteins (Grossman et al., 2003; Haenzelmann et al., 
2010), their role is still in dispute. 
 
Ubiquitin is activated by the E1 enzyme, which cleaves it after the di-glycine motif and attaches 
it to its active site cysteine by a thioester linkage. This transfer consumes ATP, making it an 
energy-dependent process. The ubiquitin moiety is then transferred to a cysteine on the E2 
enzyme, also involving a thioester linkage before being transferred to a lysine residue on the 
 
 
 
 
25 
 
 
Fig. 1.5 A schematic illustration of the ubiquitin-proteasome pathway. Ubiquitination of proteasomal 
substrate proteins is performed by a complex system consisting of ubiquitin activating (E1) enzymes, 
ubiquitin-conjugating (E2) enzymes and substrate recognition proteins (E3 enzymes). In the final step 
ubiquitin is either directly transferred from E2 to the protein substrate or via an E3 with the formation of a 
thiol ester bond between E2 and E3. The ubiquitin moiety is recycled when the cycle is complete. 
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substrate by an isopeptide linkage. In RING finger-containing E3s the role of the RING is to 
bind the ubiquitin-bound E2, bringing it into contact with the substrate which is bound by a 
separate substrate binding domain of the E3. In HECT-containing E3s the HECT domain 
interacts first with the E2, causing ubiquitin to be covalently linked to the HECT domain itself, 
and then with the substrate-binding domain, which is typically a separate protein associating with 
the HECT domain through non-covalent interactions. 
 
Substrate specificity increases as the three-step process advances. E1 interacts with all E2s, 
which interact with a more limited subset of cognate E3s. E3s in turn target a limited array of 
substrate proteins based on a shared recognition motif common to proteins being labelled. In this 
manner the ubiquitin-proteasome pathway assumes high specificity in the selection of proteins to 
be labelled (Markson et al., 2009). 
 
 1.6.1 Ubiquitin-conjugating enzymes (E2s)  
A number of ubiquitin–conjugating enzymes (UBC), also known as E2s, varies widely across 
different organisms. In the relatively small genome of Saccharomyces cerevisiae 16 genes code 
for E2-like proteins (van Wijk et al., 2010), whereas over 30 E2s have been identified in human, 
all of which share a conserved UBC domain of approximately 150 amino acid residues (Arai et 
al., 2006). Functions of these enzymes include roles in DNA repair, cell cycle progression, 
organelle biogenesis, secretion and stress response. Some of these E2s have more specific roles 
whereas others have overlapping functions. Specific functions of some E2s may be the result of 
their association with specific E3s, which in turn binds to their specific protein substrates. 
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E2s can bind directly to protein substrates or in combination with an E3. The stringency of E2-
E3 interactions depend on the identity of the E2 or E3 involved. Some E2s can interact with 
more than one E3 enzyme and some E3s can interact with several E2s. For example, using a 
structure-based yeast 2-hybrid approach, Klevit and co-workers demonstrated that the human 
RING E3 BRCA1 interacts with ten E2s (Christensen et al., 2009). Based on their observations, 
Klevit and co-workers postulated that the ability of BRCA1 to interact with more than one E2 
could be a common feature among other RING and U-box E3s. The fact that many E2s are 
capable of interacting with the same E3 demonstrates a form of functional redundancy especially 
within the E2 enzyme family which has undergone evolutionary expansion.  
 
1.6.2 Ubiquitin-protein ligases (E3s) 
Ubiquitin-protein ligases are classified into four types: namely the HECT (homologous to E6-
associated protein C-terminus), RING (really interesting new gene) or U-box (a modified RING 
motif without the full complement of Zn
2+
-binding ligands) and N-end rule E3 ligases. The first 
to be identified were the N-end rule E3 ligases which bind N-end rule protein substrates that 
have basic (Type I) or bulky hydrophobic (Type II) N-terminal amino acid residues (Baboshina 
et al., 2001). The N-end rule E3s bind proteins bearing N-termini type 1 and type II residues with 
higher affinities compared with proteins bearing other residues (Type III). Paradoxically, a 
significant fraction of eukaryotic protein degradation occurs through the N-end rule pathway, 
although the majority of cellular proteins are type III substrates. Many human N-end rule E3s 
have been characterised thus far (Kume et al., 2010; Zenker et al., 2005; Tasaki et al., 2005). 
The N-end rule recognition mechanism is strongly conserved in eukaryotic evolution (Mogk et 
al., 2007). Surprisingly, the N-end rule pathway of protein degradation has recently been 
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reported in bacteria although prokaryotes are known to be devoid of a ubiquitin system 
(Varshavsky, 2008). 
 
A second major family of E3 enzymes was originally identified by its sequence similarity to the 
C-terminal region of the E6-associated protein (E6-AP), an E3 ubiquitin-protein ligase. This 
homologous C-terminal region is a 350 amino acid-long region known as the homologous to E6-
AP C-terminus (HECT) domain. The HECT domain binds to specific E2s, accepts ubiquitin 
from the E2 to form a ubiquitin-thioester intermediate with its HECT active cysteine, and then 
transfers ubiquitin to the -amino group of a lysine side chain either directly on a substrate or to a 
ubiquitin moiety already conjugated to a substrate, producing a polyubiquitin chain. The 
formation of a thioester intermediate with Ub is unique to HECT E3s and has not been observed 
with other classes of E3s. Most HECT-domain proteins are either E3 enzymes themselves or 
form part of multi-protein complexes with E3-like activities. Examples of HECT domain 
proteins include E6AP, Nedd4 (which ubiquitinates epithelial Na
+
 channel subunits), HectH7, 
HectH6 (p532), Smurf-1, and Wwp2 (Edwin et al., 2010; Beaudenon et al., 2008; Yamashita et 
al., 2005). 
 
The third type of E3s are the RING finger motif-containing E3s. Several of these proteins have 
been shown to have E3 ubiquitin ligase activity (Deshaies et al., 2009). RING E3s interact 
simultaneously with E2 and with substrate suggesting that facilitate the recruitment of E2s to the 
vicinity of proteins to be ubiquitinated (Joazeiro et al., 2000). Interestingly, some RING finger-
containing E3s bind their cognate E2s predominantly via regions outside the RING, since 
mutations in this region are known reduce the E3 ligase activity. An example is, Ubr1p, a RING 
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finger-containing E3, which interacts with its cognate E2, Rad6p, via a region outside the RING 
finger. Mutations in the RING finger region abrogate the ubiquitination function of Ubr1p and 
yet have no effect on the binding to Rad6p and the protein substrate (Joazeiro et al., 1999). In 
light of this observation, it is thought that such RING finger domains could play an allosteric 
regulatory role with respect to the E2. 
 
The last class of E3 ligases to be classified was the U
 
box-containing E3s. These were originally 
identified as being able to extend existing ubiquitin chain but not to initiate them (Hatakeyama et 
al., 2001), but many of them have subsequently been shown to be able to initiate them as well, 
making them additional members of the E3 family. E3s classified under this type contain a U-
box domain, an approximately 70 amino acid-long domain present in proteins from yeast to 
humans, which adopts a structure identical to the RING fingers although it does not require zinc 
in order to fold. Deletion of the U-box or mutation of conserved amino acids within it abolishes 
ubiquitination activity of most U-box-containing E3s. They differ from other types of E3 ligases 
in the sense that some U-box proteins catalyze polyubiquitination by targeting lysine residues of 
ubiquitin other than lysine-48, which is utilized by HECT and RING-finger E3 enzymes for 
polyubiquitination. A well-characterized U-box containing protein is the carboxyl terminus of 
Hsc70-interacting protein, (CHIP) which was one of the first U-box containing E3s to have been 
demonstrated to possess intrinsic ubiquitin-ligase activity (Hatakeyama et al., 2001).  
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1.7 Methods for identifying and investigating protein-protein 
interactions 
Many techniques are available for investigating the interactions between proteins. These include 
genetic techniques such as yeast 2-hybrid analysis, cell biology techniques such as co-
immunoprecipitation assays and biophysical methods such as BIACore, Circular Dichroism, 
fluorescence, NMR and X-ray crystallography.  
 
1.7.1 Protein-protein interactions as probed by NMR  
Biomolecular NMR spectroscopy has proven to be a powerful tool in characterising 
biomolecular interactions, including transient and weak ones that usually escape other 
characterisation approaches (Vaynberg et al., 2006). One of the most attractive advantages of 
biomolecular NMR is that the information obtained is resolved down to the level of individual 
amino acids. NMR can therefore be used to map protein-protein interfaces as well as to 
determine the structures of dynamic protein complexes that are difficult to crystallise and those 
which may crystallise in a non-biological conformation. 
 
A number of parameters can be employed in biomolecular NMR for the investigation of protein-
protein interactions and solution of structures of protein complexes. These include nuclear 
overhauser effects (NOEs), residual dipolar couplings (RDCs), chemical shift perturbations 
(CSPs) and paramagnetic relaxation enhancements (PREs). Of these, CSPs are the most widely 
used for protein-protein interactions (McCoy et al., 2002). This involves the acquisition of NMR 
spectra of an isotope-labelled protein alone and when bound to an unlabelled ligand. The ligand 
 
 
 
 
31 
 
can be a short synthetic peptide or a heterologously expressed recombinant protein. The CSPs 
provide a per residue characterisation of the protein-protein interface and enable the local effects 
and conformational dynamics associated with ligand binding to be closely studied. In addition, 
CSPs allow for the binding affinities between interacting proteins to be quantified. The CSP data 
obtained from NMR can also be used in conjuction with data-driven docking procedures to solve 
the structures of protein complexes. In one approach, known as HADDOCK, CSP data are 
translated into ambiguous interaction restraints to drive the docking process (van et al., 2006). 
The CSP interaction restraints can be combined with residual dipolar coupling (RDC) data, 
allowing a better definition of the relative orientation of the components (van Dijk et al., 2005). 
For example, the 95 kDa complex of the acyltransferase protein with the acyl carrier protein has 
been modelled based on CSP data and RDCs (Jain et al., 2004).    
     
1.7.2 Yeast two-hybrid (Y2H) 
The yeast two-hybrid (Y2H) system is a molecular genetic test which utilises the reconstitution 
of an active transcription factor to assay for protein-protein interactions (Causier, 2004). The 
Y2H system is based on the finding that some eukaryotic transcription factors have separable 
DNA-binding (BD) and transcription activation domains (AD) which can be physically separated 
and reconstituted, fused to exogenous proteins known as bait and prey respectively. Interaction 
between the bait and prey proteins reconstitutes the active transcription factor, producing a 
positive read-out of down-stream reporter genes (Fig. 1.6). 
 
Fields and co-workers were the first to develop the Y2H technique in the study of protein-protein 
interactions (Fields et al., 1989). They utilised a product of the yeast gene GAL4, a protein with  
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Fig. 1.6 An illustration of the classical yeast two-hybrid system. Two plasmids are constructed, one 
encoding the test protein X fused in-frame with the DNA-binding domain (BD) of a transcription factor 
such as GAL4, the second plasmid encoding test protein Y fused in-frame with the transcription 
activation domain (AD). The plasmids are co-transformed into a suitable yeast strain where the fusion 
proteins are expressed. Interaction between X and Y reconstitutes an active transcription factor which 
specifically binds to elements upstream of the reporter genes and activates their expression. Adapted from 
(Causier et al., 2002). 
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two functional domains that activate transcription of genes involved in galactose metabolism. 
The BD of the GAL4 protein binds to DNA sequences within the promoter region of GAL1 and 
the AD of the GAL4 protein stimulates transcription. Fields and Song constructed two separate 
plasmids, containing the cDNA sequence coding for the DNA-binding domain of GAL4 
(GAL4BD) fused in-frame to DNA sequences coding for the yeast protein SNF1. The other 
plasmid containing the sequence coding for the transcriptional activating domain of GAL4 
(GAL4AD) fused in-frame to DNA sequences coding for the yeast protein SNF4. They introduced 
these two plasmids into a yeast strain containing the lacZ reporter gene from E. coli fused to the 
GAL1 promoter. Interaction between SNF1p and SNF4p allowed the GAL4 activating domain to 
activate the transcription of the lacZ gene. The resulting -galactosidase activity was detected by 
the formation of blue yeast colonies on medium supplemented with the chromogenic substrate 5-
bromo-4-chloro-3-indolyl--D-galactopyranoside (X-Gal) (Fields et al., 1989). 
 
The Y2H technique offers a number of advantages over other biochemical procedures used to 
analyse protein-protein interactions. It is relatively inexpensive, since it avoids costly procedures 
such as antibody production and protein purification. The sensitivity of Y2H is better than that of 
many in vitro techniques and hence it is more suited for the detection of weak and transient 
interactions, which are commonly found in signalling cascades (Piehler, 2005). Importantly, 
proteins expressed using in vitro techniques or in bacteria often lack key post-translational 
modifications that may be important for certain protein-protein interactions and these proteins 
may not fold correctly or may not be stable in the buffer conditions used in in vitro techniques. 
Since the yeast is a eukaryote and the screen takes place in vivo, many of these limitations do not 
apply.  
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One of the most appealing features of the Y2H is that the interacting protein does not have to be 
cloned following identification, but is already available in a convenient plasmid. Y2H plasmids 
typically contain flanking regions coding for immune-affinity tags and promoters for in vitro 
expression of proteins.  
 
The technique is not without limitations, however, since transcription events only happen within 
the nucleus, it is necessary that both the bait and prey are capable of localising to the nucleus. 
Consequently the technique may not be suitable for interactions involving membrane proteins, 
which are unlikely to be soluble in the nucleus. Also, the incidence of false positives in Y2H is 
common since some proteins are promiscuous interactors and also because some proteins have 
intrinsic transcriptional activation activity. Mechanisms for eliminating or controlling for these 
false positives are therefore necessary. In addition, the yeast cell environment may not fully 
mimic mammalian cells; for example, post-translational modifications may not be replicated in 
yeast. Therefore, as with most scientific tools, it is imperative for results derived using the Y2H 
technique to be confirmed by independent methods. 
 
In a yeast 2-hybrid screen, cDNA libraries are cloned into pACT2 vector and a screen is carried 
out to identify prey proteins interacting with the bait protein. In a direct yeast 2-hybrid assay a 
smaller number of proteins or mutants are directly tested for their ability to interact with the bait 
protein. This format is especially useful for investigating the effects of mutations on a known 
interaction. In this case the presence of a positive control (the previously identified wild type 
interaction) makes many of the disadvantages described above irrelevant. 
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1.7.3 Co-immunoprecipitation (Co-IP) assays  
Co-immunoprecipitation is one of the oldest and most widely used technique for studying 
protein-protein interactions. It uses the specificity of antibodies to isolate target proteins out of 
complex sample mixtures with  the antibodies therefore being isolated using protein A or protein 
G coupled to agarose or sepharose beads (Berggard et al., 2007). Complexes containing the 
target protein, antibody, protein A or G and beads are then isolated by centrifugation. Protein 
components in the complexes are visualized by Western Blotting or autoradiography in the case 
of radio-labelled proteins. If an antibody against the protein of interest is not available, 
recombinant DNA technology can be used to incorporate immunoaffinity tags of 10-20 amino 
acids in length into the protein (Angers et al., 2002). Common peptide tags include 
hemagglutinin (HA) or Myc epitopes for which antibodies are commercially available. A typical 
co-IP assay involves subjecting a mixture of the two putatively interacting proteins to 
immunoprecipitation using an antibody against one of the one of the proteins and western 
blotting using an antibody against the second protein. If the second protein is observed when the 
first protein is present, but not when it is absent, the interaction is confirmed. 
  
 
1.8 Justification and aims of the study 
YB-1 has recently assumed great significance in cancer, mainly through its role in directing the 
transcription of a large number of genes that facilitate the development of tumours. High levels 
of YB-1 are a recognised marker of poor prognosis for the patient, suggesting that therapies 
aimed at targeting YB-1 may be a promising approach for combating cancer. Through its 
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interaction with the C-terminus of YB-1, RBBP6 mediates the ubiquitination and degradation of 
YB-1, thereby making RBBP6 a potential effecter of such an approach. As a means of initiating 
such a strategy, a number of questions first need to be answered, including: how strong is the 
interaction, how does the interaction contribute to ubiquitination of YB-1, which residues from 
each protein are involved in the interaction, and what is the effect of mutating them on the 
interaction itself and on the cell as a whole. This thesis aims to answer two of these questions: 1. 
Can the interaction be validated and the strength of the interaction measured using NMR, and 2. 
Which residues are involved. 
 
A previous Y2H screen identified the interaction between RBBP6 and YB-1 and demonstrated 
that it is localized to a 62 amino acid region at the C-terminus of YB-1. This study will firstly use 
Y2H, co-IP and NMR to investigate whether the RBBP6/YB-1 interaction can be localised to a 
region smaller than the 62 amino acid region at the C-terminus of YB-1. 
 
Secondly this study will also attempt to shed light on the mechanism of ubiquitination of YB-1. 
Previous in vitro ubiquitination assays in HEK 293 cells were not able to identify which of the 
human E2 proteins were responsible for ubiquitination of YB-1 by RBBP6. This study will 
therefore use an in vitro reconstituted ubiquitination assay with a panel of different E2 enzymes 
to identify which ones co-operate with RBBP6 in ubiquitinating YB-1. 
 
Finally, this study aims to construct mutants which abolish the homodimerisation of the RING 
finger domain. NMR-based structure studies show that the RING finger-like domain of RBBP6 
is a homodimer in solution (Pugh et al., unpublished data). Many RING finger and U-box 
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domains are known to be homodimers and in a number of cases homodimerisation has been 
shown to be essential for ubiquitination activity. In order to test whether this is true in the case of 
RBBP6, non-dimeric mutants first need to be generated and validated. This study aims to use 
NMR to investigate the oligomeric state of two different mutants of the RING finger-like domain 
of RBBP6. 
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Chapter 2: Materials and methods 
2.1 General chemicals and enzymes  
All the reagents used in this study were of analytical grade.  
 
40%  37.5:1 Acrylamide:bis-acrylamide    Bio-Rad 
Agarose        Lonza 
Ammonium persulphate (APS)      Merck 
Ampicillin        Roche 
Bacteriological agar       Merck 
Bovine serum albumin      Roche 
Bromophenol blue       Sigma 
Coomasie brilliant blue R250      Sigma 
Dithiothreitol (DTT)       Roche 
DNase         Roche 
Ethylene diamine tetra acetic acid (EDTA)    Merck 
EDTA-free protease inhibitor cocktail    Roche 
Ethanol        BDH 
Ethidium bromide       Sigma 
Glacial acetic acid       Merck 
Glucose        BDH 
Glycine        BDH 
Herring sperm DNA       Promega 
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Hydrochloric acid (HCl)      Merck 
Isopropyl -D-thiogalactopyranoside (IPTG)   Roche 
Kanamycin monophosphate      Roche 
L-adenine hemisulphate      Sigma 
Lithium acetate       Sigma 
Lysozyme        Roche 
Methanol        Merck 
MG132 (proteasome inhibitor)     Sigma 
Potassium chloride       Merck 
Phenylmethylsulphonyl fluoride (PMSF)    Roche 
Protein molecular weight standard     Fermentas 
Reduced glutathione (GSH)      Sigma 
Restriction enzymes       Fermentas 
Sodium dodecyl sulphate (SDS)     Promega 
Sodium azide        Roche 
Sodium chloride       Merck 
Sodium hydroxide       Merck 
Synthetic dropout supplements (SD)     Clontech 
T4 Ligase        Fermentas 
TEMED (N, N, N`, N`- Tetra methylethylene-diamine)  Promega 
Tris (Tris[hydroxymethyl] aminoethane)    BDH 
Triton X-100 (Iso-octylphenoxypolyethoxyethanol)   Roche 
Tryptone        Merck 
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Tween 20 (Polyoxyethylene [20] sorbitan)    Merck 
Yeast extract        Merck 
Yeast nitrogen base       Clontech 
Zinc sulphate        Merck 
 
 
2.2 Synthetic peptides 
Synthetic peptides used in this study (CTD-1 and CTD-2) were purchased from GenScript 
Corporation
®
 (Piscataway, NJ, USA). 
 
 
2.3 Stock solutions, buffers and media 
Autoclaving of solutions was carried out at 120˚C for 20 min unless otherwise stated. 
4x Separating gel Buffer: 
1.5M Tris-HCl, pH 8.8. 
4x Stacking gel Buffer: 
0.5M Tris-HCl, pH 6.8.  
5x M9 salts 
13.6 g Na2HPO4, 6.0 g KH2PO4, 1.0 g NaCl, 2.0 g NH4Cl in 400 ml of Millipore water. 
5X SDS Running Buffer: 
25 mM Tris, 0.1% SDS and 250 mM glycine, pH 8.3. 
6X DNA loading dye: 
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0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol were mixed in distilled water. 
10X Phosphate-buffered saline (PBS): 
80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 2.4 g KH2PO4, was dissolved by stirring in 800 mls of 
deionised water. The solution was adjusted to pH 7.4 with HCl and filled up to 1 litre with 
distilled water. The solution was sterilised by autoclaving at 120˚C for 20 min.  
Ammonium persulphate: 
A 10% stock solution was prepared in deionised water. 
Ampicillin: 
A 100mg/ml stock solution was prepared in distilled water. 
Cell lysis Buffer: 
150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5.0 mM DTT, 200 g/ml lysozyme, 35 g/ml DNase, 
1.0 mM PMSF, 5.0 mM EDTA, 2% Triton X-100, 2 tablets or EDTA-free cocktail of protease 
inhibitors.  
Cleavage Buffer 1: 
0.1M borate buffer, pH 8.5 fortified with 0.5 M NaCl. 
Cleavage Buffer 2: 
0.1M acetate buffer, pH 4.5 fortified with 0.5 M NaCl. 
Chloramphenicol: 
A 100 mg/ml stock solution was prepared in absolute ethanol. 
Co-IP Buffer 
12.5 l of aprotinin (2mg/ml stock solution), 50 l DTT from a 100 mM stock solution, 50 l of 
50 mM PMSF solution, 5 l of tween-20. The volume was made up to 5 ml with 1X PBS. 
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Coomassie staining solution: 
0.25 g coomassie brilliant blue R250, 45 % methanol and 5 % acetic acid dissolved in water. 
Destaining solution:  
30 % methanol and 10 % acetic acid in water. 
DTT: 
A 1M stock solution was prepared in 0.01 M sodium acetate, pH 5.2 and sterilised by filtration. 
EDTA: 
A stock solution of 0.5 M, pH 8.0 was prepared in distilled water. 
Elution Buffer (GSH): 
15 mM GSH, 50 mM Tris-HCl pH 8.0.  
IPTG (Isopropyl -D-thiogalactopyranoside): 
A 1 M stock solution was prepared in deionised water and sterilised by filtration.  
Luria bertani media (LB media): 
10 g/l Tryptone, 5.0 g/l yeast extract, 5.0 g/l NaCl and 2 g/l glucose. Solution was sterilised by 
autoclaving. 
LB agar plates: 
31 g/l nutrient agar, 2 g/l glucose, 5 g/l NaCl, 5 g/l yeast extract, 10 g/l tryptone was dissolved in 
1.0 litre of water and sterilised by autoclaving. The medium was allowed to cool and 100 g/ml 
of ampicillin was added and then poured into sterile plates in a biolaminar flow (Labotec, South 
Africa).   
Lysozyme:  
50 mg/ml of lysozyme solution was prepared in deionized water. 
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15
N-labelled minimal media: 
20 % Glucose, 1 M CaCl2, 1 M MgSO4, 400 ml of 5x M9 salts in 2 Litres of distilled water and 
sterilised by autoclaving. 
NMR Buffer:  
100 mM phosphate buffer fortified with 50 mM NaCl, 0.02 % NaN3, 5 mM DTT, 100 µM 
ZnSO4. 
PreScission
TM
 3C protease cleavage Buffer:  
50 mM Tris-HCl, pH 7.0, 150 mM NaCl, 5.0 mM DTT, 1.0 mM EDTA. 
TBST Buffer 
150 mM NaCl, 20 mM tris-HCl pH 8.0, 0.1 % tween-20 in double distilled water. 
Tfb1 Buffer: 
30 mM potassium acetate, 50 mM MnCl2, 0.1 M KCl, 6.7 mM CaCl2, and 15 % (v/v) glycerol.  
Tfb 2 Buffer:   
9 mM MOPS,10 mM KCl, 50 mM CaCl2, and 15 % (v/v) glycerol. 
TYM Broth: 
20 g/l tryptone, 5 g/l yeast extract, 3.5 g/l NaCl, 2 g/l MgCl2. 
Yeast single amino acid drop-out media agar: 
2 % (w/v) glucose, 2 % (w/v) nutrient agar, 0.67 % (w/v) yeast nitrogen base, 0.067 % (w/v) 
single drop-out (SDO) amino acid supplement, 1 mM NaOH dissolved in double distilled water 
and sterilised by autoclaving at 120˚C for 20 minutes before plating. 
Yeast single drop-out liquid media: 
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2 % (w/v) glucose, 20 g/l nutrient agar, 0.67 % (w/v) yeast nitrogen base, 0.067 % (w/v) single 
drop-out (SDO) amino acid supplement, 1 mM NaOH dissolved in double distilled water and 
sterilised by autoclaving at 120˚C for 20 minutes. 
Yeast double drop-out media agar: 
2 % (w/v) glucose, 2 % (w/v) nutrient agar, 0.67 % (w/v) yeast nitrogen base, 0.067 % (w/v) 
synthetic double drop-out (DDO) amino acid supplement (-L-W), 1 mM NaOH dissolved in 
double distilled water and sterilised by autoclaving at 120˚C for 20 minutes before plating. 
Yeast double drop-out liquid media: 
2 % (w/v) glucose, 2 % (w/v) nutrient agar, 0.67 % (w/v) yeast nitrogen base, 0.067 % (w/v) 
synthetic double drop-out (DDO) amino acid supplement (-L-W), 1 mM NaOH dissolved in 
double distilled water and sterilised by autoclaving. 
Yeast triple drop-out agar media: 
2 % (w/v) glucose, 0.67 % (w/v) yeast nitrogen base, 0.067 % (w/v) synthetic triple drop-out 
(TDO) amino acid supplement (-L-W-H), 2 % bacterial agar, 1 mM NaOH dissolved in double 
distilled water and sterilised by autoclaving. 
YPDA liquid media: 
2 % (w/v) Difco peptone, 2 % (w/v) yeast extract, 2 % (w/v) glucose, 0.003 % L-adenine 
hemisulphate, dissolved in double distilled water and sterilised by autoclaving.  
 
 
2.4 Commercial antibodies 
Rabbit anti-HA MAb antibody (sc-805) and mouse anti-cMyc MAb antibody (sc-40) were 
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 
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2.3 Plasmid vectors 
2.3.1 pACT2 AD vector 
The pACT2 AD vector (Clontech, Mountain View, CA, USA) shown in Fig. 2.1 is a shuttle 
vector that replicates autonomously in both E.coli and S. cerevisiae and contains the bla gene, 
which confers ampicillin resistance in E. coli. pACT2 AD (also commonly referred to as 
pACT2) also contains a LEU2 nutritional gene that allows yeast auxotrophs to grow on limiting 
synthetic media. In Y2H assay it is used for the cloning of cDNA of prey proteins. It generates a 
fusion of the GAL4 AD, an HA immunoaffinity tag and a protein of interest cloned into the MCS 
in the correct orientation and reading frame. In yeast host cells, expression of the hybrid protein 
is driven by the ADH1 promoter (P) and is terminated at the ADH1 transcription termination 
signal (T) (shown in Fig. 2.1).  The protein is targeted into the yeast nucleus by the nuclear 
localization sequence from the SV40 T-antigen which has been cloned into the 5′-end of the 
GAL4 AD sequence. 
 
2.3.2 pGBKT7-R 
The pGBKT7 vector (shown in Fig. 2.2) expresses proteins fused to the GAL4 DNA-binding 
domain (DNA-BD). In yeast, expression of the fusion proteins is driven by the ADH1 promoter 
(PADH1); transcription is terminated by the T7 and ADH1 transcription termination signals (TT7 
and TADH1). pGBKT7 also contains the T7 promoter, a c-Myc epitope tag and a multiple cloning 
site. pGBKT7 replicates autonomously in both E. coli and S. cerevisiae from the pUC and 2  
ori, respectively. The vector carries the kanamycin resistance gene for selection in E. coli and the 
TRP1 nutritional marker for selection in yeast. 
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Fig. 2.1 The restriction map of pACT2 AD vector (Clontech) for cloning cDNA of prey proteins 
used in the yeast two-hybrid. The figure shows the restriction map and multiple cloning site (MCS) of 
pACT2 AD vector. The GAL4 activating domain (GAL4 AD) and the HA epitope tag are immediately 
upstream of the MCS. 
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Fig. 2.2 Restriction map and main features of pGBKT7 vector (Clontech). The figure shows the 
restriction map and multiple cloning site (MCS) of the pGBKT7 vector. The immunoaffinity tag c-Myc is 
immediately upstream of the MCS. pGBKT7 vector also contains the cDNA of the GAL4 DNA-binding 
domain (GAL4 DNA-BD) and the kanamycin resistance gene. 
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2.3.3 pGEX-6P-2 
pGEX-6P-2 (GE Healthcare, Waukesha, WI, USA) (Fig. 2.3) is a bacterial protein expression 
vector that expresses GST fused proteins. It has a multiple cloning incorporating six restriction 
sites, facilitating the unidirectional cloning of cDNA inserts. pGEX-6P-2 encodes the recognition 
sequence for the PreScission™ Protease in the linker region between the GST domain and the 
MCS which allows for removal of the GST from the fusion protein by enzymatic cleavage. The 
cleavage of fusion proteins by the PreScission™ Protease occurs between the Gln and Gly 
residues of the recognition sequence Glu-Val-Leu-Phe-Gln-Gly-Pro. The vector pGEX-6P-2 also 
incorporates an IPTG inducible tac promoter for high-level expression.  
 
 
2.4 Bacterial cultures  
2.4.1 Bacterial strain chromosomal genotype 
E. coli MC1061 (Casadaban et al., 1980): 
F
-
, araD139, (ara leu) 7697, Δlacx74, galU-, galK-, hsm+, strA.  
E. coli BL21 Star
TM
 pLysS (DE3) (Studier et al., 1986): 
 F
-
, omp T hsdSB(rB
-
mB
-
) gal dcm rne131 (DE3) (Stratagene, La Jolla, CA, USA). 
E. Coli strain DH5α  (Taylor et al., 1993): 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17. 
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Fig. 2.3 Reading frame and main features of pGEX-6P-2. Protein coding sequences cloned in frame 
into the MCS of pGEX-6P-2 are fused to the C-terminus of Glutathione S-transferase (GST) gene. The 
vector has a PreScission™ 3C Protease recognition sequence immediately downstream of the GST-
coding sequence. It also contains an ampicillin resistance gene and a bacterial origin of replication.  
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E. coli MC1061 and DH5α cells were used for propagation of plasmid DNA, and E. coli BL21 
Star
TM
 pLysS (DE3) cells were used for the heterologous expression of recombinant proteins. 
The bacterial cultures were grown at 37 ˚C in LB medium and LB agar plates with or without 
ampicillin. The ampicillin was used at a final concentration of 100 g/ml. 
 
2.4.2 Preparation of competent cells for transformation 
A single E. coli colony was taken from a freshly streaked agar plate and transferred to 10 ml of 
TYM broth and grown at 37 ˚C in a shaking incubator to an OD550 of 0.2. The culture was then 
scaled up to 500 ml of TYM broth and grown at 37 ˚C in a shaking incubator to an OD550 of 0.2. 
The culture was cooled by gently swirling on ice and the bacteria were sedimented by 
centrifugation at 5000 g for 10 min at 4 ˚C. The bacterial pellet was then re-suspended in 250 ml 
of transformation buffer 1 (Tfb1) on ice and left for 30 min with intermittent swirling. The 
mixture was centrifuged at 5000 g for 10 min at 4 ˚C and the resultant pellet was re-suspended in 
50 ml of transformation buffer 2 (Tbf2) on ice. 300 l aliquots of the mixture were transferred 
into 1.5 ml eppendorf tubes and quick frozen in liquid nitrogen. The snap-frozen aliquots were 
then stored at -80 ˚C until they were needed for transformation. 
 
2.4.3 Bacterial transformation with plasmid DNA 
Competent cells stored at -80 ˚C were thawed on ice and 100 l of competent cells were added to 
plasmid DNA in a 1.5 ml eppendorf tube. This mixture was then incubated on ice for 30 min. An 
identical tube containing cells but no plasmid DNA was set up as a control. After the 30 min 
incubation period the bacteria were transformed by heat shock at 37 ˚C for 5 min on HB/01 
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digital heating blocks (Omeg Scientific, Somerset West, South Africa) and immediately placed 
back on ice. The transformation reaction was left on ice for 5 min to allow the cells to recover. 
To each of the tubes, 900 l of pre-warmed LB without ampicillin was added and incubated at 
37 ˚C in a shaking incubator for 90 min. 100 l of each transformation was plated on an LB agar 
plate with 100 g/ml ampicillin and then incubated at 37 ˚C for 16 hours. 
 
2.4.4 Extraction of plasmid DNA  
Plasmid DNA from transformed E. coli cells was extracted using the Wizard
®
 Plus SV Miniprep 
Kit (Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions. 
The assessment of purity and quantification of the concentration of Plasmid DNA was carried 
out using the NanoDrop
®
 ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies Inc., 
Wilmington, DE, USA). 
 
2.5 Manipulation of plasmid DNA 
2.5.1 Primer design 
The designing of primers for the amplification of target genes was done manually, based on the 
human coding sequences. The forward primers incorporated a BamHI restriction site and the 
reverse primers a Xho I restriction site. A stop codon was included in all reverse primers. 
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2.5.2 Amplification of DNA by PCR  
The polymerase chain reaction (PCR) was used for the amplification of gene segments from their 
respective cDNA sequences. All PCR reactions were done using the GeneAmp
®
 PCR system 
(Applied Biosystems Inc., Foster City, CA, USA). EconoTaq™ DNA polymerase (Lucigen® 
Corporation, Middleton, WI, USA) was used for the amplification of DNA unless otherwise 
stated. 
 
2.5.3 Analysis of DNA  
The assessment of the purity and yield of (i) PCR products and (ii) plasmid DNA extractions was 
carried out using agarose gel electrophoresis. 10 l of the DNA sample was mixed with 5 l of 
2X DNA loading dye. The mixture was then loaded into 0.8 - 1 % agarose slab gels containing 1 
g/ml of ethidium bromide. The agarose gel was then placed in a tank containing 1X TAE buffer 
and an electric field of 100 V was applied until the dye front reached the end of the gel. The 
DNA bands were visualized using a gel documentation system equipped with a long wave UV 
transilluminator (BioRad Laboratories Inc., Hercules, CA, USA). 
 
2.5.4 Purification of DNA 
PCR products were cleaned up using the Illustra™ GFX™ PCR DNA and Gel band purification 
Kit (GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s instructions.  
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Table 2.1 PCR reaction set up for the amplification of DNA fragments 
Reaction components (Final 
concentrations) 
Control Reaction 
Vol. (l) 
Experimental reaction Vol. 
(l) 
1X Taq polymerase reaction 
buffer 
10 10 
Forward primer and Reverse 
primer  
(0.4 M each) 
1 (each) 1 (each) 
dNTPs 
(0.4 mM each) 
2 2 
Millipore water 11 11 
Econo Taq™ DNA polymerase 
(0.5 *Units/l) 
1 1 
Template DNA  
(2 ng/l) 
 -  1 
Total Volume 25 25 
*One unit is defined as the amount of the Econo Taq™ polymerase that catalyses the incorporation of 10 
nmol of dNTP into acid insoluble material in 30 minutes at 70 °C. 
 
2.5.5 Restriction enzyme digestion 
PCR amplified products and destination vectors were digested with FastDigest™ restriction 
enzymes Bam HI and Xho I (Fermentas International Inc. Ontario, Cananda) unless otherwise 
mentioned. 30 l of either PCR amplified product or the destination vector and 2 l each of Bam 
HI and Xho I were added to 5 l of 10X restriction enzyme digestion buffer. The reaction 
volume was made up to 50 l per reaction with double distilled water after which the reaction 
tubes were incubated at 37 °C for 30 min on a HB/01 Digital heating block (Omeg Scientific, 
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Somerset West, South Africa). The digested DNA was then purified as described in section 5.4 
so as to remove the restriction digestion buffer and prevent it from interfering with downstream 
cloning processes. 2 l of Shrimp alkaline Phosphatase (SAP) (New England Biolabs® Inc., 
Ipswich, MA, USA) and 5 l of 10x SAP reaction buffer was added to the destination vector to 
prevent self-religation of vector DNA. SAP dephosphorylates sticky ends of restriction enzyme-
digested plasmid vectors. 
 
2.5.6 Ligation of DNA 
Insertion of target DNA into destination vectors was performed using T4 DNA ligase (Fermentas 
International Inc. Ontario, Cananda). For any given insert, three ligation reactions were set up, 
each with a different insert:vector ratio: 1:3, 1:5, and 3:1. In each ligation reaction, 1 l of T4 
DNA ligase and 2 l of 10X ligation buffer were added together and the ligation reaction volume 
scaled up to 10 l with double distilled water. A vector-only ligation reaction was also set up 
which did not contain the insert so as to monitor the vector background corresponding to self-
religation of the plasmid vector. The ligation reaction was pulse-spun in a benchtop centrifuge 
5415D (Eppendorf International, Hamburg, Germany) before incubation at 4°C for 16 hours. 
 
2.5.7 Screening for positive clones  
Ten colonies were picked at random from the ligation ratio with had the largest number of 
colonies. A small scale extraction of DNA was carried out and the presence of insert was tested 
by PCR using gene-specific primers. Positive colonies were sent for sequencing (Inqaba 
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Biotec™, Pretoria, South Africa) to further confirm the presence of desired insert. Sequence 
analysis was done using 4 peaks software (Mekentosj, Aalsmeer, The Netherlands).  
 
2.6 Co-immunoprecipitation  
2.6.1 In vitro synthesis of bait and prey proteins.  
PCR-amplified cDNA sequences of bait and prey proteins were used as templates for in vitro 
synthesis of their respective proteins. Preys were amplified using pACT2 primers, generating 
products incorporating the bacteriophage T7 promoter and HA-epitope tag sequence.Baits were 
amplified using pGBKT7 primers, generating products incorporating the bait, bacteriophage T7 
promoter and Myc-epitope tag sequence.  
 
In vitro coupled transcription/translation, was carried out using the TNT
® 
T7 Quick Coupled 
transcription/translation system (Promega Corporation, Madison, WI, USA), according to the 
manufacturer’s instructions. Each translation reaction contained 7 µl of the PCR-generated DNA 
template, 40 µl of the TNT
® 
T7 Quick master mix, 1 µl of PCR S30 T7 enhancer and 2 µl 
35
S-
methionine (GE Healthcare, Buckinghamshire, UK). The mixture was incubated at 30 °C for 90 
minutes using a dry block heater HB2 (Hagar designs, Wilderness, South Africa). To verify the 
integrity of the products, the translated proteins were separated on an SDS-PAGE gel and 
visualized using autoradiography. 
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2.6.2 In vitro co-immunoprecipitaion of bait and prey proteins 
5 µl each of 
35
S-methionine-labelled bait and prey proteins were mixed together in a 500 µl 
eppendorf tube and incubated for at least 1 hour at room temperature. 10 µl of agarose-
conjugated Myc antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was then 
added to the mixture, the volume adjusted to 250 µl with co-IP buffer. The mixture was 
incubated for 1 hour at 4 °C on a rotating rotor (Labnet Inc., Edison, NJ, USA) and then 
centrifuged for 30 sec at 10 000g on a Beckman Microfuge lite (Beckman Inc., Brea, CA, USA). 
The supernatant was discarded and then the pellet was washed 5 times using TBST. The washed 
pellet was mixed with 10 µl sample buffer and boiled for 5 min before loading on a 12.5 % SDS-
PAGE gel and visualized using autoradiography. 
 
 
2.7 Yeast 2-hybrid methods 
2.7.1 Yeast strains used 
Yeast strain AH109 phenotype (James et al., 1996) 
MA Ta, trp1-901, lue2-3, 112, ura3-52, his3-200, gal4D, gal80D, LYS2 : : GAL1UAS-GAL1TATA-
HIS3, GAL2UAS-GAL2TATA-ADE2, URA3 : : MEL1UAS-MEL1TATA-lacZ. 
Yeast strain Y187 phenotype (Harper et al., 1993) 
MA Ta, ura3-52, his3-200, ADE2-101, trp1-901, leu2-3, 112, gal4D, met
-
, gal80D, URA3 : : 
GAL1UAS-GAL1TATA-lacZ. 
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2.7.2 Transformation of yeast 
All strains used were Saccharomyces cerevisiae strains. A loopfull of yeast cells was re-
suspended in 1 ml of sterile Millipore water, the mixture was and then pelleted by centrifugation 
for 30 sec at maximum speed using a bench-top centrifuge (Beckman Coulter, Brea, CA, USA). 
The supernatant was discarded and the pellet was re-suspended in 1ml of 100 mM LiAc and then 
incubated at 30 ˚C for 5 mins without shaking. 50 l of the mixture was transferred into a 2 ml 
round-bottomed eppendorf tube and the cells pelleted by spinning for 20 sec at maximum speed 
in a bench top centrifuge and the LiAc removed using a pipette. 240 l of 50 % poly ethylene 
glycol (PEG), 36 l of 1 M LiAc, 25 l herring-sperm DNA were then added to the pellet along 
with 20 l of transforming DNA. (Note: LiAc makes the yeast cell wall more porous so that they 
are better able to take up plasmid DNA, while PEG protects against the harmful effect of the 
concentrated LiAc. The Herring Sperm DNA acts as a carrier of the plasmid DNA). 
 
The mixture was vortexed for at least 1 min to break up the pellet and expose as many of the 
yeast cells as possible to the transformation mix and thereby increase the transformation 
efficiency. The transformation tubes were incubated in a water bath (Lasec, Cape Town, South 
Africa) at 42 ˚C for 25 min. The cells were pelleted for 30 sec in a bench top centrifuge at 
maximum speed and the supernatant discarded. The cells were then re-suspended in 250 l 
sterile Millipore water and 150 l of this mixture was then plated on appropriate agar plates to 
select for the plasmid transformed into yeast. The plates were incubated upside down in a Sanyo 
MIR262 ventilated incubator (Sanyo Electronic company Ltd, Ora-Gun, Japan) at 30 ˚C for 4 
days. 
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2.7.3 Yeast mating 
Yeast strains Y187 and AH109 are of opposite mating types, and when mated give rise to diploid 
yeast cells. 5 ml of pre-transformed yeast cell cultures of opposite mating types were mixed 
together and the volume adjusted to 50 ml by adding 2X YPDA media containing 10 µg/ml 
kanamycin. The mating culture was then incubated at 30 ˚C for 24 hours with shaking at 30 g in 
a YIH DER model LM-510R shaking incubator (SCILAB instrument Co. Ltd, Taipei, Taiwan), 
after which 200 µl of the culture was plated onto 150 mm TDO plates. The TDO plates were 
incubated at 30 ˚C for 7 days in a Sanyo MIR262 ventilated incubator (Sanyo Electronic 
company Ltd, Ora-Gun, Japan). 
 
 
2.8 Recombinant protein expression 
2.8.1 Small scale protein expression 
Four freshly transformed colonies of E. coli BL21 pLysS (DE3) were inoculated into 10 ml LB 
media containing 100 g/ml ampicillin and grown in a shaking incubator (ZHWY-211C model, 
Zhicheng
®
 manufacturers, Shanghai, China) for 2 hours at 37 ˚C. Each culture was divided into 
two 5 ml cultures of which one was induced with 0.5 mM IPTG and both cultures were then 
allowed to grow for 4 hours. Pellets from the uninduced and induced cultures were then screened 
for protein expression using SDS-PAGE.  
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2.8.2 Large scale protein expression 
A 500 l aliquot from the small-scale expression culture was inoculated into 100 ml of LB 
medium containing 100 g/ml ampicillin and incubated at 37 ˚C overnight in a shaking incubator 
(ZHWY-211C model, Zhicheng
®
 manufacturers, Shanghai, China). In the morning, the 
overnight culture was scaled using 900 ml of fresh LB containing 100 g/ml ampicillin was 
added and allowed to grow at 37 ˚C in a shaking incubator until an OD550 of 0.4-0.5 was reached. 
IPTG was added to a final concentration of 0.5 mM, the temperature lowered to 25 ˚C and the 
culture grown for 5 hours after which the cells were harvested by centrifugation using a 
Beckman centrifuge J2-21 model (Beckman Coulter, Brea, CA, USA) at 10 000 g for 30 min. 
The supernatant was discarded and the cells re-suspended by gently vortexing in 30 ml of cell 
lysis buffer. The cells were lysed by the freeze thaw method by freezing the cell suspension at -
70 ˚C for 5 min and subsequently thawing it at 37 ˚C for 5 min, with the cycle repeated 3 times. 
The cell suspension mixture was then centrifuged at 1000 g for 30 min to obtain the crude lysate. 
Immediate purification of the lysate was done so as to minimise degradation by bacterial 
proteases. 
 
2.8.3 Expression in 
15
N-labelled minimal media  
A 500 l aliquot from the small scale expression culture was inoculated into 100 ml of LB 
medium containing 100 g/ml ampicillin and the culture was incubated at 37 ˚C overnight in a 
shaking incubator (ZHWY-211C model, Zhicheng
® 
manufacturers, Shangai, China). In the 
morning the cells were harvested by centrifugation in a Beckman centrifuge (J2-21 model, 
Beckman Coulter, Brea, CA, USA) at 3000 g for 10 min and the supernatant discarded. The 
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pellet was then re-suspended in 1 litre minimal media and allowed to grow at 37 ˚C in a shaking 
incubator. When an OD550 of approximately 0.4 was reached, 100 M ZnSO4 was added. When 
OD550nm reached 0.5, IPTG was added to a concentration of 0.5 mM and the incubation 
temperature was lowered to 25 ˚C and the cells grown overnight. The cells were harvested by 
centrifugation at 10000 g for 30 min and lysed by the freeze thaw method as described above. 
 
 
2.9 Glutathione affinity chromatography 
Glutathione affinity chromatography was used for the purification of GST-tagged recombinant 
proteins using a gravity-fed self-packed column. 
 
2.9.1 Preparation of glutathione affinity column 
Dry glutathione agarose beads (Sigma, St. Louis, MO, USA) were swelled according to the 
manufacturer’s instructions and poured into a plastic gravity-fed column. 
 
2.9.2 Purification of the crude lysate 
The column was washed with 3 column volumes (CV) of 1 M NaCl and then equilibrated with 5 
CV of 1X PBS. The crude lysate was added to the column and 1 CV of the non-bound fraction 
was collected as the ‘flow through’ from the column. The column was then washed with 6 CV of 
1X PBS, with samples from the beginning and end being collected (wash and clean wash 
respectively) for further analysis. The bound protein was eluted from the column with 1 CV of 
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15 mM glutathione in 50 mM Tris-HCl, pH 8.0 and 5 fractions (1 CV each) were collected. 
Finally the column was washed with 2 CV of 2 M NaCl and two 1 CV fractions were collected. 
All of the collected fractions were analysed by SDS-PAGE. 
 
2.9.3 Cleavage of recombinant protein 
Fractions containing the fusion protein were pooled and dialysed against 2 litres of Cleavage 
Buffer (50 mM Tris-HCl, 150 mM NaCl, 5.0 mM DTT, 1.0 mM EDTA, pH 7.0) using a 3 500 
MWCO. SnakeSkin
®
 pleated dialysis tubing (Thermo Scientific, Rockford, IL, USA). After 1 
hour, 50 l of home-made PreScission™ 3C Protease was added to the dialysis bag to separate 
the GST from the target protein and incubated overnight at 4°C with gentle stirring. Following 
cleavage, the contents of the dialysis bag were returned to the glutathione column and the target 
protein collected in the flow through, with GST being retained on the column. (Note: Dialysis 
serves the dual function of removing glutathione resulting from the first affinity step as well as 
changing to Cleavage Buffer).   
 
2.9.4 Size exclusion chromatography 
Following removal of most of the GST in the second glutathione affinity step, residual GST was 
removed by size exclusion chromatography on a Hi Prep
TM
 16/60 Sephacryl
TM
 S-100 High 
Resolution column (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). The column was 
equilibrated with 1 CV of NMR buffer at a flow rate of 0.75 ml/min. The sample was 
concentrated into 1 ml using an Amicon
®
 Ultra-15 centrifugal filter device with a MWCO of 
3000 Da (Millipore
®
 Corporation, Billerica, MA, USA) and injected onto the column. 1 ml 
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fractions were collected and analysed by SDS-PAGE. Fractions containing the desired protein 
were pooled together and concentrated into 600 µl for NMR analysis. 
 
 
2.10 SDS-PAGE 
The integrity and purity of protein fractions were analysed by SDS-PAGE as described by 
Laemmli (Laemmli, 1970) using a BioRad Mini-PROTEAN
®
 3 system (BioRad Laboratories, 
Hercules, CA, USA). 16% separating gels and 4% stacking gels were made by mixing different 
components as shown in the table below: the separating gel was poured into the assembled 
BioRad system and allowed to set, after which the stacking gel was added on top and ten well 
combs were used to form the wells for loading the protein samples to be analysed. Molecular 
weights were estimated with the aid of protein molecular weight standards (Fermantas, Hanover, 
MD, USA) 
 
20 l aliquots of protein were mixed with 10 l of 2x SDS Sample Buffer, vortexed briefly and 
boiled at 95 ˚C for 5 mins. 20 l of the boiled mixture was loaded into the wells and separated 
using a potential of 100 V until the dye front reached the end of the gel. The gel was removed 
from the assembly and stained in a solution of Coomasie Brilliant Blue R250 for at least 1 hour, 
where after it was destained in destaining solution overnight. Electronic copies of SDS-PAGE 
gels were produced by scanning. 
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Table 2.2 Components used for 4% stacking gels and 16% separating gels for SDS- PAGE 
Component Volume added (ml) 
(4% Stacking Gel) 
Volume added  
(16% Separating Gel) 
Double didstilled H2O          6.1 ml            6.4 ml 
1.5 M Tris, pH 8.8 (Separating Buffer)              -          5.25 ml 
0.5 M Tris, pH 6.8 (Stacking Buffer)          2.5 ml                 - 
40% Acrylamide          1.5 ml               8 ml 
10% SDS         100 l           210 l 
10% APS           50 l            120 l 
TEMED           20 l             25 l  
 
 
2.11 Determination of protein concentration  
The protein concentration was determined using the Quick Start™ Bradford Protein Assay Kit 
(BioRad Laboratories, Hercules, CA, USA) in the 1 ml format according to the manufacturer’s 
instructions. Absorbance readings were taken at 595 nm using a Helios Epsilon 
spectrophotometer (Thermo Spectronic, Madison, WI, USA) blanked against NMR Buffer. 
Commercially prepared samples of bovine gamma globulin with concentration of 10, 20, 30, 40, 
50, 80, 90, 100 µg/ml were used as standards. Two dilutions (1:400 and 1:800) of the protein 
sample were prepared and their absorbance readings taken according to the instructions on the 
kit. Plots of OD590nm as a functions of concentration in g/ml were generated using Microsoft 
Excel (Microsoft
®
 Corporation, Redmond, WA, USA) and fitted to straight lines with y intercept 
= 0. 
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2.12 Methods in biomolecular NMR  
2.12.1 Sample preparation 
All NMR experiments were carried out in NMR Buffer, AT 25 °C using a Varian Inova 600 
MHz spectrometer equipped with a 14.1 T 51-mm bore Oxford Magnet (Varian Inc., Palo Alto, 
CA, USA). 600 l samples were pipetted into 8 inch long, 5 mm-diameter Wilmad NMR tubes 
(Sigma-Aldrich, St. Louis, MO, USA) and 7 % (v/v) deuterium oxide (D2O) was added to act as 
a lock signal. Lyophilised synthetic peptides (GenScript Corporation, Piscataway, NJ, USA) 
were re-suspended in double de-ionised water to give stock concentrations of 10 mM for both 
CTD-1 and CTD-2. 40 minute 
1
H-
15
N-HSQC spectra were recorded using the gnhsqc pulse 
sequence which forms part of the BioPack suite (Varian, Palo Alto, CA, USA), with 4 transients, 
128 t1-increments, 1024 points in the direct time dimension, a 
1
H spectral width of 8000 Hz and 
a 
15
N spectral width of 2000 MHz. Spectra were processed using NMRDraw (Delaglio et al., 
1995) and displayed using NMRView (Johnson et al., 1994).  
 
2.12.2 NMR titration experiments 
A series of 
1
H-
15
N-HSQC spectra of the 
15
N-labelled RING finger domain were collected, one 
following each addition of unlabelled peptide. Peptides were added in 10 µl aliquots and the final 
concentration calculated taking into account the increased sample volume. 
1
H-
15
N-HSQC spectra 
were overlayed so as to identify the residues that displayed significant chemical shift 
perturbations during the titration. Co-ordinates of the centres of resonance were extracted using 
NMRView and chemical shift perturbations plotted as a function of ligand concentration using 
pro Fit (Uetikon am See, Switzerland). Curves were fitted to the theoretical expression 
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and values extracted for KD using an experimentally measured value for [P]. Here [P] denotes the 
total protein concentration, [L] the total ligand concentration and KD the dissociation constant of 
the interaction. 
 
 
2.13 In vitro ubiquitination assays 
Components of the ubiquitin reaction were set up as shown in Table 2.3.E1 enzyme and pre-
coupled Mg-ATP solution were obtained commercially from Boston Biochem Inc. (Cambridge, 
MA, USA). E2 enzymes were obtained commercially from the E2 enzyme kit (Product code K-
980, BostonBiochem). 
35
S-labelled substrate (YB-1) was expressed using the TNT
®
 In vitro 
transcription/translation kit (Promega Corporation, Fitchburg, WI, USA) according to the 
manufacturer’s instructions. Bacterially expressed RING finger-like domain was used as the E3 
enzyme. Proteasome inhibitor MG132 was added to block degradation of ubiquitinated proteins. 
The reaction was then incubated at 37 °C for 90 min using a rotating rotor at 10 g (Labnet Inc., 
Edison, NJ, USA) and ubiquitinated forms of 
35
S-YB-1 were detected using SDS-PAGE 
followed by autoradiography. 
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Table 2.3 Components of the ubiquitination assay 
Component Experimental Reaction  Control Reaction  
50 mM HEPES buffer pH 
8.0 
15 µl 15 µl 
E1 200 nM 200 nM 
E2 1 µM  -  
E3 (RING finger) 1 µM 1 µM 
Substrate (YB-1) 1 µM 1 µM 
MG132 
(protease inhibitor) 
10 µM 10 µM 
Ubiquitin aldehyde 5 µM 5 µM 
Ubiquitin 1 mM 1 mM 
Mg-ATP solution (ERS) 10 µl 10 µl 
A separate reaction was set up for each E2 enzyme being tested. The control reaction had all of the same 
components with the exception of the E2 enzyme. ERS – is the energy regeneration solution. 
 
2.14 Generation of RING mutants 
Expression constructs encoding for mutated RING finger-like domain were generated by 
GenScript Corporation, Piscataway, NJ, USA) using wild type constructs supplied by the 
researcher. Mutant constructs were generated in pCMV plasmids and sub-cloned into pGEX-6P-
2 for bacterial expression of the protein.   
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Chapter 3: Investigation of the interaction between the RING finger 
of RBBP6 and YB-1 
3.1 Introduction 
YB-1 was previously identified as an interaction partner of RBBP6 in a yeast 2-hybrid screen 
using the RING finger-like domain of RBBP6 as bait (Chibi et al., 2008). Based on the cDNA 
sequence of the Y2H prey vector, the RBBP6/YB-1 interaction was found to be localised within 
the last 62 amino acid residues of the C-terminal domain of YB-1, residues 262 - 324 (here 
designated as the YB-1Y2H region). This study aims to shed light on the RBBP6/YB-1 interaction 
at the amino acid level using three different assays: a direct yeast 2-hybrid assay, NMR chemical 
shift perturbation and co-immunoprecipitation.  
 
3.2 Analysis of the interaction between YB-1 and the RING finger 
domain of RBBP6 using a Yeast 2-hybrid assay 
A panel of peptides derived from the YB-1Y2H region were designed with the aim of testing their 
interaction with the RING finger domain of RBBP6 using a direct yeast 2-hybrid approach. The 
peptides were designated as YB-1261-291, YB-1277-306, and YB-1292-324 respectively. Another 
fragment devoid of the last 62 amino acids at the C-terminus was also designed and this was 
designated as YB-1∆62. The point of including YB-1∆62 in the Y2H assay was to investigate if 
RBBP6 also interacts with regions of YB-1 outside the region identified by the original yeast 2-
hybrid screen. 
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3.2.1 Generation of YB-1 derived fragments 
cDNA fragments corresponding to YB-1261-291, YB-1277-306, and YB-1292-324 were PCR amplified 
from the prey plasmid recovered by Chibi and co-workers in the previous yeast 2-hybrid screen. 
The primers used for this amplification are shown in Table 3.1. Primers were designed based on 
the nucleotide sequence of human YB-1 (GenBank accession number AAH98435). YB-1∆62 was 
amplified from a full length cDNA construct kindly donated by Dr. Moredreck Chibi, CNRS, 
University of Paris.  
 
The amplifications of YB-1277-306 and YB-1292-324 were successfully carried out (see Fig.3.2) and 
these were then cloned into the yeast prey expression vector pACT2 as described in section 
2.5.6. The constructs were sequenced and found to be 100 % correct (see Appendix II and III). 
The amplifications of YB-1∆62 and YB-1261-291 were unsuccessful because of faulty primer 
design.   
 
3.2.2 Direct yeast 2-hybrid assay 
The pGBKT7-RING plasmid encoding the RING finger-like domain of RBBP6 was a kind gift 
from Dr. Moredreck Chibi. The bait and prey expression plasmids were transformed into yeast 
strains of opposite mating types as described in section 2.7.2. pGBKT7-RING (bait) was 
transformed into AH109 and preys pACT2-YB-1277-306, pACT2-YB-1292-324, pACT2-YB-1Y2H 
and empty pACT2 were transformed into the yeast strain Y187. Empty pACT2 vector was used 
as a negative control while pACT2-YB-1Y2H was used as a positive control. Bait and prey-
transformed strains were mated as described in Section 2.7.3 and the resultant diploid colonies  
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Fig. 3.1 An illustration of the designed fragment peptides tested for interaction with the RING 
finger domain of RBBP6. The figure shows the amino acid boundaries of the fragment peptides. The 
fragments are not drawn to scale. The fragment devoid of the last 62 C-terminal amino acid residues of 
YB-1 (YB-1∆62) is shown in (A). The last 62 amino acid region of the C-terminal domain of YB-1 is 
represented by YB-1Y2H (B). (C), (D), and (E) show the amino acid boundaries of YB-1261-291, YB-1277-
306, and YB-1292-324 whose interaction with the RING finger domain of RBBP6 was being tested for. 
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Table 3.1 Primers used for the amplification of YB-1-derived fragments 
Primer name Primer sequences 
YB-1∆62 
Forward 
5′-GAGACGGATCCAAATGAGCAGCGAGGCCGAGA-3′ 
YB-1∆62 
Reverse 
5′-TTATCCCTCGAGTTATTCTTCATTGCCGTCCTCTCT-3′ 
YB-1261-291 
Forward 
5′-GGGCAAGGATCCAAGAAGATAAAGAAAATCAAGGAG-3′ 
YB-1261-291 
Reverse 
5′-AGGGTCCTCGAGTTAGCGTCTGCGTCGGTAATTG-3′ 
YB-1277-306 
Forward 
5′-AGTGTGGATCCCTCAACGTCGGTACCGC-3′ 
YB-1277-306 
Reverse 
5′-ATTGTCTCGAGTTAGGCTGCTTTTGTCTCTTTGC-3′ 
YB-1292-324 
Forward 
5′-CCTGAGGATCCCAGAAAACCCTAAACCACAA-3′ 
YB-1292-324 
Reverse 
5′-GTCTCCTCGAGTTACTCAGCCCCGCCCTG-3′ 
 
 
The nucleotide sequence shown in black font represents the sequence of the primer that is complimentary 
to the DNA template used in the PCR reaction. The green colour represents the nucleotide overhang tag 
that facilitates restriction enzyme digestion while the red and blue colours correspond to the restriction 
enzyme recognition site and the stop codon respectively.   
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Fig. 3.2 A 1 % agarose gel image showing PCR amplification of YB-1277-306 and YB-1292-324. Lanes 2 
and 3 correspond to the amplicons of YB-1277-306 and YB-1292-324 respectively. Lane 1 shows the 
negative control of the PCR reaction that had no DNA template in it and lane M corresponds to the DNA 
molecular weight marker. The expected size of both YB-1277-306 and YB-1292-324 is approximately 90 bp 
long. 
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were first grown on double drop-out plates and then transferred into media of higher stringency 
lacking 3 amino acids (triple drop-out - TDO). 
 
Diploid yeast cells containing bona fide interacting bait and prey proteins are expected to grow 
in TDO media.  Fig. 3.3 shows that diploid cells containing YB-1Y2H were able to grow well on 
TDO plates as expected. Cells containing YB-1292-324 grew moderately well whereas YB-1277-306 
grew poorly on TDO plates. We conclude that YB-1277-306 interacts with the RING finger 
domain, and that YB-1292-324 interacts poorly, if at all.  
 
 
3.3 Analysis of the interaction between YB-1 and the RING finger 
domain of RBBP6 using co-immunoprecipitaion assays 
The YB-1-derived fragments YB-1277-306  and YB-1292-324  were tested for their interaction with 
the RING finger domain of RBBP6 using co-immunoprecipitation (co-IP) assays. 
35
S-labelled 
proteins expressed as fusions with immunoaffinity tags were expressed using an in vitro 
transcription/translation kit (Promega, Corporation, Fitchburg, WI, USA).  
 
3.3.1 Expression of proteins for use in the co-IP assay 
pACT2-YB-1277-306 and pACT2-YB-1292-324 were used as templates to PCR-amplify cDNA for 
the in vitro expression of HA-YB-1277-306 and HA-YB-1292-324 respectively. pGBKT7-RING was 
used to produce cDNA for the expression of cMyc-RING. The primers used in the PCR reactions 
are shown in Table 3.2. In addition to the epitope tags, the amplified sequences incorporate 
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Fig. 3.3 A yeast 2-hybrid assay showing that YB-1277-306 and YB-1292-324 interact with RING finger 
in vivo. Yeast diploid colonies containing prey plasmids pACT2-YB-1277-306 and pACT2-YB-1292-324 
(panels 1 and 2) were able to grow on TDO medium in the presence of pGBKT7-RING. This means that 
RING interacts with YB-1277-306 and YB-1292-324. Diploid colonies with pACT2-YB-1Y2H and pGBKT7-
RING (panel 3) acted as a positive control of the yeast 2-hybrid experiment while those containing empty 
pACT2 served as negative control. The brown colouration in panel 4 is a sign of dying yeast cells that are 
unable to survive in TDO media. Empty pACT2 is unable to code for bait and prey proteins therefore 
diploid cells containing empty pACT2 fail to survive in TDO media. Diploid yeast cells are able to grow 
in TDO if they contain interacting bait and prey proteins. 
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bacteriophage T7 promoters from the host vectors for use in the in vitro expression system. 
Amplification of HA-YB-1292-324, HA-YB-1Y2H, and Myc-RING was successful (see Fig. 3.4) but 
the generation of HA-YB-1277-306 was unsuccessful. The corresponding protein fragments were 
produced in a cell-free system as described in Section 2.6.1. Fig. 3.5 shows that HA-YB-1292-324 
(lane 1), HA-YB-1Y2H (lane 2) and Myc-RING (Lane 4) were successfully expressed. 
 
 
Table 3.2 Primers for the PCR amplification of bait and prey inserts 
Primer 
name 
Primer sequence and primer annealing temperature (°C)  
pGBKT7 
Forward 
5′-AATAAAATTGTAATACGACTCACTATAGGGCGAGCCGCCACCATGGAGGAGC 
AGAAGCTGATGTCA-3′ 65°C 
pGBKT7 
Reverse 
5′-TCACTTTAAAATTTGTATACAC-3′ 44°C 
pACT2 
Forward 
5′-AATAAAATTGTAATACGACTCACTATAGGGCGAGCCGCCACCATGTACCCA 
TACGACGTTCCAGAT-3′ 61°C 
pACT2 
Reverse 
5′-GGGGTTTTTCAGTATCTACGAT-3′ 52°C 
 
3.3.2 RING finger co-immunoprecipitates YB-1292-324  in vitro   
Radio-labelled HA-YB-1Y2H or HA-YB-1292-324 were mixed with Myc-tagged RING in a co-IP 
experiment and the results analysed using autoradiography (see Fig. 3.5). Anti Myc was able to 
precipitate HA-YB-1292-324 in the presence but not in the absence of Myc-RING (see lane 5, Fig. 
3.5). Myc-RING was also able to precipitate HA-YB-1Y2H (lane 6) as expected from the previous 
Y2H screen. 
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Fig. 3.4 A 1% agarose gel showing the amplification of cDNA of proteins to be subjected for co-IP 
analysis. The amplicons of the cDNA of test proteins were amplified by PCR as fusions of cDNA of 
immunoaffinity tags. Lane 1 shows the negative control of the PCR reaction that had no template DNA in 
it. Lane 2 shows the cDNA of HA-YB-1292-324, while lanes 3 and 4 contain the cDNA of HA-YB-1Y2H. 
Lane 5 shows the cDNA of Myc-RING. The DNA molecular weight marker is shown in lane M.  
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Fig. 3.5 An autoradiograph showing the immunoprecipitation of in vitro generated 
35
S-labelled 
proteins. The antibodies used to precipitate the proteins are shown in each respective lane. Lanes 1 and 2 
respectively correspond to individual immunoprecipitates of HA-YB-1292-324 and HA-YB-1Y2H 
precipitated with anti-HA (αHA) antibody. Lane 4 corresponds to co-immunoprecipitation of Myc-RING 
with anti-Myc antibody. Lanes 5 shows Myc-RING and HA-YB-1292-324 which were co-
immunoprecipitated with anti-Myc antibody. This indicates that RING and YB-1292-324 interact together in 
vitro. Co-immunoprecipitation of RING and YB-1Y2H is shown in lane 6 which acts as a positive control 
for the co-IP assay. Lane 3 corresponds to the negative control of the assay in which HA-YB-1292-324 and 
HA-YB-1Y2H were not precipitated by anti-Myc (αMyc) antibody itself. 
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Although the quantities of YB-1 peptides precipitated by Myc-RING are small, lanes 1 and 2 
suggest that the total amount of the peptides present in the reactions was not large, and so the 
results do not necessarily imply that the interactions are weak. 
 
 
3.4 Analysis of the interaction between YB-1 and the RING finger 
domain of RBBP6 using NMR spectroscopy 
Synthetic peptides CTD-1 and CTD-2 derived from YB-1Y2H were tested for their interaction 
with bacterially expressed 
15
N-labelled RING finger domain using NMR chemical shift 
perturbation analysis. The amino acid sequences and percentage purities of these synthetic 
peptides are shown in Table 3.3. The amino acid boundaries of these synthetic peptides relative 
to YB-1Y2H are shown in Fig. 3.6. CTD-1 and CTD-2 were designed to correspond as closely as 
possible (given the constant of solubility) to peptides YB-1262-291 and YB-1277-306 used in the 
yeast 2-hybrid and co-IP studies.    
Table 3.3 Synthetic peptides and their amino acid composition 
Peptide Amino acid composition % Purity 
CTD-1 EDKENQGDETQGQQPPQRRYRRNFNYRRRR 99.2 
CTD-2 PENPKPQDGKETKAADPPAENSSAPEAEQGGAE 98.5 
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Fig. 3.6 An illustration of the synthetic peptides tested for interaction with the RING finger domain 
of RBBP6 using 
1
H-
15
N-HSQC NMR. The figure shows the amino acid boundaries of the fragment 
peptides relative to YB-1Y2H. CTD-1 and CTD-2 were tested for interaction with 
15
N-labelled RING. A 
Shows the YB-1Y2H fragment and its amino acid boundaries. B and C show the amino acid boundaries for 
the synthetic peptides CTD-1 and CTD-2 respectively.  
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3.4.1 Expression and purification of the RING finger domain of RBBP6 for 
use in NMR 
The RING finger domain was expressed as a GST fusion protein using the pGEX-6P-2 vector 
system (GE Healthcare, Waukesha, WI, USA). The pGEX-6P-2-RING expression construct was 
cloned and kindly provided by Takalani Mulaudzi (Department of Biotechnology, UWC). E. coli 
BL21 (DE3) pLysS cells were transformed with pGEX-6P-2-RING as described in Section 2.4.3 
and screened for the recombinant protein expression as described in Section 2.8.1. Fig 3.7 shows 
the result of small-scale expression assays for 4 different colonies. The uninduced lysates are 
shown in lanes 1, 3, 5, and 7 while lanes 2, 4, 6, and 8 show the induced lysates. A prominent 
band of approximately 36.8 kDa, corresponding to GST-RING (GST - 26.6 kDa, RING - 10.2 
kDa), is seen in the induced lanes but not in the un-induced lanes.  
 
500 l from the small-scale expression culture shown in lanes 7 and 8 of Fig. 3.7 was inoculated 
into 100 ml of 
15
N-labelled minimal media as described in Section 2.8.3. GST-RING was 
purified away from E. Coli’s native proteins using glutathione-affinity chromatography as 
described in Section 2.9.2. Fig. 3.8A shows that high levels of expression were obtained. The 
GST-RING fusion protein was cleaved using 3C protease (Fig. 3.8B lane 2) and GST and 
uncleaved fusion protein (lanes 6-9) were removed by a second glutathione-affinity step, while 
free RING finger domain was collected in the flow through (Fig. 3.8B lanes 3 and 4). Flow-
through fractions were pooled together in preparation for downstream purification steps. 
Residual GST and other contaminating proteins were removed from RING by size exclusion 
chromatography (Fig 3.9A) as described in Section 2.9.4.  
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Fig. 3.7 SDS-PAGE analysis of the small-scale expression of GST-RING in a 16 % acrylamide gel. 
Lanes 1, 3, 5, and 7 show uninduced protein expression. Lanes 2, 4, 6 and 8 show the induced protein 
expression. Lane M contains a protein molecular weight marker. The induced expression is characterised 
by the presence of a prominent band at 36.8 kDa which is absent in the uninduced lanes. 
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Fig. 3.8 Large-sale expression, affinity purification and cleavage of GST-RING using PreScission™ 
3C Protease. (A) Expression of GST-RING in minimal media. Lane 1 shows the crude lysate whilst lane 
2 shows the flow through, lane 3 shows the column wash, lanes 4-8 each correspond to the fractions 
eluted from the GST column. Lane 9 shows the fraction eluted during the NaCl wash. Lane M shows the 
protein molecular weight marker. (B) Lane 1 shows the uncleaved fusion protein, lane 2 shows the 
cleaved protein and lanes 3 and 4 both show the flow through, containing predominantly the isolated 
RING finger domain. Lane 5 corresponds to the column-wash, while lanes 6 and 7 show what was eluted 
with 10 mM glutathione. Lane M shows the protein molecular weight marker. The isolated DWNN 
domain has previously been reported to migrate at an anomalously large apparent molecular weight (M.A. 
Kappo, PhD thesis, UWC 2009) 
A 
B 
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Fig. 3.9 Purification of RING finger domain by size exclusion chromatography. (A) Peak 1 and 2 correspond to 
GST and RING finger domain respectively. (B) SDS-PAGE analysis of the fractions from the FPLC. Lane 1 
corresponds to the unpurified protein sample before purification, lane 3 corresponds to the fraction at the top of Peak 
1. Lanes 2, 4, 5, 6, and 7 correspond to some of the fractions eluted under peak 1. Lane 8 corresponds to the fraction 
at the beginning of Peak 2 while lane 9 corresponds to the fraction at the top of Peak 2. (C) SDS PAGE gel of 
purified RING finger domain after gel filtration. Lane M in all the gels corresponds to the protein molecular weight 
marker. 
B  
 
A 
 
C  
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Since the GST(MW 26.6 kDa) has a higher molecular weight than that of the RING finger 
domain (10.2 kDa), it eluted earlier than the RING finger domain, as expected, and a clear 
separation between GST (peak 1) and RING (Peak 2) was achieved as shown in Fig 3.9A. 
Fractions were collected and their contents assessed by SDS-PAGE analysis as shown in Fig. 
3.9B. Fractions containing pure RING finger were pooled and concentrated into 600 µl for NMR 
analysis. Fig 3.9C shows that the final sample of RING finger domain was highly pure.  
 
Note: the RING finger-like domain migrates on SDS-PAGE gels at an apparent molecular 
weight of 18 kDa rather than the expected 10.2 kDa. This has been noted previously and is a 
feature of this protein. 
 
3.4.2 Determination of protein concentration 
The concentration of the expressed sample was determined by the Bradford method as described 
in Section 2.11. The absorbance readings of standard protein concentrations (Table 3.4) were 
used to construct the standard curve shown in Fig. 3.14. All the absorbance readings were taken 
at 595 nm. The equation y = 0.0043x – 0.008 was used to determine the concentration of the 
RING finger domain protein preparations. 
 
At 1:800 dilution of the RING finger domain the absorbance was found to be 0.201 (Table 3.4) 
which, using the standard curve, corresponds to 48.6 µg/ml, which is equivalent to an original 
concentration of 38.9 mg/ml. At 1:400 dilution of the RING finger domain, the absorbance was 
found to be 0.3675 (Table 3.4), which is equivalent to an original concentration of 34.9 mg/ml. 
Since the molecular weight of RING finger domain is 10.2296 kDa the molar concentrations of  
 
 
 
 
84 
 
Table 3.4 Absorbance values for the gamma globulin standards and RING 
Concentration (g/ml) Absorbance at 595 nm 
Gamma globulin Standards  
10 0.0135 
20 0.070 
30 0.1385 
40 0.1785 
50 0.212 
80 0.3615 
90 0.376 
100 0.401 
Sample dilutions  
1:400 0.3675 
1:800 0.201 
 
 
Fig. 3.10 Gamma globulin standard curve for the determination of the protein concentration of the 
RING finger domain. A595 values of the standard protein (gamma globulin) plotted against different 
concentrations of gamma globulin. The unknown concentration of RING was determined using the A595 
values at different dilutions. The equation of the standard curve was used to calculate the concentration of 
RING finger domain. 
 
 
 
 
 
85 
 
the RING finger domain protein preparations translate to 3.8 mM and 3.4 mM respectively. 
Averaging the two values gives the concentration as 3.6 mM. 
 
3.4.4 RING interacts with YB-1 through part of its C-terminal helix. 
NMR chemical shift perturbations were used to map the YB-1 binding site onto the RING finger 
domain. Fig. 3.11 shows that CTD-1 induced small but concentration-dependent shifts on the 
1
H-
15
N-HSQC spectrum of 
15
N-labelled RING finger domain. Perturbations were plotted as a 
function of concentration (Fig. 3.12) and fitted to the expected theoretical expression given in 
Section 2.12.2. The values of KD and total perturbation for the most affected residues are given 
in Table 3.5.  
 
The values of KD and the total chemical shift perturbation for the most affected residues are 
shown in Table 3.5. Most of them fall in the region 324-330, which lie along an extended surface 
on the face of the homodimer adjacent to the C-terminal helix (see Fig. 3.14). Structural analysis 
and 
15
N-relaxation studies (Pugh et al., unpublished data) show that this surface is rigid and 
structured, and is therefore a potential interaction surface for YB-1. Fig.3.13 shows that CTD-2 
produced perturbations that are broadly consistent with those produced by CTD-1, but of a 
smaller magnitude, which suggests a weaker interaction between CTD-2 and the RING finger-
like domain of RBBP6. 
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Table 3.5 KD values and total chemical shifts 
Residue Total chemical shift change (ppm) KD (M) 
Asn
324
 0.065 176 
Glu
325
 0.056 487 
Thr
326
 0.145 263 
Gly
327
 0.047 256 
Tyr
328
 0.087 334 
Thr
329
 0.078 117 
Lys
330
 0.054 455 
 
 
Fig. 3.11 Overlay of 
1
H-
15
N-HSQC spectra of 
15
N-labeled RING with increasing concentration of 
unlabelled CTD-1 peptide. Chemical shift perturbations are characteristic of an interaction between 
substrate and ligand. The RING residues Asn
324
, Glu
325
, Thr
326
, Gly
327
, Tyr
328
, Thr
329
, and Lys
330
 are 
perturbed the most owing to binding to the CTD 1 peptide. Backbone assignment of resonances was 
carried out by Pugh et al., unpublished data. 
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Fig. 3.12 Composite chemical shifts of residues of the RING finger domain of RBBP6 that displayed 
significant perturbations on titration with CTD-1.
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Fig. 3.13 Overlay of 
1
H-
15
N-HSQC spectra of 
15
N-labeled RING with increasing concentration of 
CTD-2 peptide.  
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Fig. 3.14 Surface representation of the homodimer of the RING finger-like domain of RBBP6 
showing the YB-1 binding site. The localisation of the residues (Asn
324
, Glu
325
, Thr
326
, Gly
327
, Tyr
328
, 
Thr
329
, and Lys
330
) interacting with CTD-1 are shown in purple. These residues lie along an extended 
surface on the face of the homodimer adjacent to the C-terminal helix. The end view of the molecule is 
shown in A) while the side view of the same molecule is shown in B). In both views the YB-1 binding 
site is shown in dark purple in one monomer and in light purple in the other monomer.  
 
 
 
 
 
 
 
 
 
A B  
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Chapter 4: Functional investigations 
4.1 Identification of cognate RBBP6 E2s using an in vitro 
ubiquitination assay 
RBBP6 was previously shown to act as an E3 ubiquitin ligase in the ubiquitination of YB-1 in 
HEK 293 cells (Chibi et al., 2008). Human cells contain 35 different E2 enzymes, any of which 
could be involved in ubiquitinating YB-1. Establishment of a fully in vitro assay for 
investigating RBBP6-mediated ubiquitination of YB-1 requires that active E2s be identified so 
that they can be expressed in bacteria for use in in vitro assays. In order to identify the E2 
involved, a preliminary small scale screen of 3 different E2s was carried out. The E2s selected 
were UbcH5c, UbcH7 and Ubc13. UbcH5c was chosen for screening because it is the most 
promiscuous of the E2s, meaning that it is active in many ubiquitin reactions in conjuction with 
many different E3s. UbcH7 is a known cognate E2 of c-Cbl, a RING finger containing E3-ligase 
(Zheng et al., 2000). Ubc13 shares the S-P-A motif also found in UbcH5c, which has been 
proposed as a determinant of E2s active with the CHIP family of E3 ligases (Xu et al., 2008). 
Since the RING finger domain of RBBP6 is highly similar to the U-box domain of CHIP (Pugh 
et al., unpublished data), Ubc13 may also be expected to be active in conjuction with RBBP6. 
UbcH7 does not contain the S-P-A motif and therefore may be expected not to have activity in 
conjuction with RBBP6.  
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4.1.1 UbcH5c and UbcH7 facilitate YB-1 ubiquitination in vitro 
Human E2s UbcH5c, UbcH7 and Ubc13 were tested for activity in the ubiquitination of YB-1 in 
vitro as described in Section 2.13.  In vitro translated/transcribed YB-1 was used as a substrate, 
incorporating 
35
S-methionine to facilitate detection by autoradiography.  The RING finger 
domain which was used as the E3 in this assay was produced by in vitro transcription/translation 
but without radioactive labelling. Fig. 4.1 shows that addition of UbcH5c produces a ladder of 
higher molecular weight bands above YB-1 that is suggestive of ubiquitination. Contrary to 
expectation, UbcH7 also appears to produce ubiquitination, whereas Ubc13 does not. 
 
 
4.2 Investigation of the effect of mutagenesis on the homodimeric 
state of the RING finger 
Previous structural studies indicate that the RING finger domain of RBBP6 is a homodimer in 
solution (Pugh et al., unpublished data). Homodimerisation of some RING finger domains and 
other U-boxes has been shown to affect the ubiquitination activity of this class of E3s (Deshaies 
et al., 2009; Zhang et al., 2005; Poyurovsky et al., 2007; Zhang et al., 2005), although the reason 
for this still remains elusive. In order to be able to probe the effect of the homodimer on 
ubiquitination, we sought to design mutants which abrogate the dimerisation. This was done by 
introducing single amino acid substitutions at the RING dimer interface. 
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Fig. 4.1 An autoradiograph showing the ubiquitination of YB-1 in the presence of different E2s. 
UbcH5c produces higher molecular weight bands above YB-1 (lane 2) consistent with ubiquitinated 
species that are not present when it is absent (lane 1). Similar but fainter bands are seen in the case of 
UbcH7 (lane 3) but not Ubc13 (lane 4). The RING finger domain from RBBP6 (E3), E1, ubiquitin, 35S-
YB-1 and ATP were present in all lanes. 
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In homologous structures such as CHIP, an asparagine corresponding to N312 of RBBP6 is 
located close to the dimer interface and forms hydrogen bonds with its counterpart in the other 
monomer. Replacement of this residue with an aspartic acid (N312D) should produce a -/- 
electrostatic repulsion, thereby possibly breaking the dimer. The structure also suggests that 
lysine 313 makes a salt bridge with D255 or E256 in the opposite monomer. Substituting lysine 
313 with a glutamate residue (K313E) should replace the salt bridge with -/- repulsion, thereby 
breaking the dimer. Mutations corresponding to N312D and K313E were therefore introduced 
into the pGEX-RING expression construct and verified by sequencing (Appendix IV and V). 
15
N-labelled mutants were then produced in bacteria in the same manner as for wild type RING.  
 
Previous NMR investigations have revealed concentration-dependant chemical shift perturbation 
resonances in the 
1
H-
15
N-HSQC spectra corresponding to residues involved in the dimerisation 
interface (M.A. Kappo, PhD thesis, UWC 2009). This data suggests that there could be an 
exchange between the monomer and the dimer which happens at a rate faster than the timescale 
for NMR observations, resulting in a population-average between the spectra of the fully 
monomeric and fully dimeric species respectively. The result is a single resonance located at the 
population-weighted average of the two spectra. 
15
N-relaxation studies confirmed that the low 
concentration limit corresponds to the monomer, and the high concentration limit to the dimer, as 
expected (Atkinson, A., unpublished data).  
 
The findings of this study show that the 
1
H-
15
N-HSQC spectra of both RING
N312D
 and 
RING
K313E
 mutants approximate the low concentration limit of the dilution series more closely 
than that of the high concentration limit, suggesting that both mutants were monomeric. This is 
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particularly clear in the case of RING
K313E
, in which the mutated residue lies near the edge of the 
dimerisation interface and therefore is not likely to have much effect other than disruption of the 
dimer. Fig. 4.3A shows that the green resonances which correspond to RING
K313E
, lie close to 
the low concentration limits of a number of residues which shift significantly on dilution.  
 
RING
N312D
 on the other hand, lies at the centre of the dimerisation interface and the mutation 
may be imputed to have effects on the 
1
H-
15
N-HSQC spectrum over and above disruption of the 
dimer. The monomeric nature of both RING
N312D
 and RING
K313E
 was confirmed by 
15
N-
relaxation experiments (Atkinson, A., unpublished data).
 
 
 
 
Fig. 4.2 A schematic illustration of the effect of concentration on resonances from the 
1
H-
15
N-HSQC 
spectrum of the RING finger domain of RBBP6. Since the monomer and dimer are in fast exchange, 
the position of the peak reflects the fraction of molecules in the dimeric state, which changes as a function 
of concentration limit, which is unattainable since it corresponds to zero concentration, corresponds to 
pure monomer; the high concentration limit, which is also unattainable since it corresponds to infinite 
concentration, corresponds to pure dimer. The RING
K313E
 mutant approximates the low concentration 
limit  
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Ile272
Ala311
Val270 Val271
Asn277
Leu309
A B
 
Fig.4.3 NMR analysis of the residue resonances of the RING
K313E
 mutant on an 
1
H-
15
N-HSQC 
spectra. A) shows an 
1
H-
15
N-HSQC overlay of the wild type RING dilution series with that of  
RING
K313E
. The green resonances correspond to residues of RING
K313E
 and these lie close to the low 
concentration limits of a number of residues which shift significantly on dilution. The chemical shifts and 
the KD values of the residues that exhibited significant perturbations are shown in (B). 
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Chapter 5: Discussion and Conclusions 
5.1 In vitro investigation of the RBBP6/YB-1 interaction 
This study investigates the structural basis underlying the interaction between the RING finger 
domain of RBBP6 and YB-1. Preliminary yeast 2-hybrid studies concluded that the RBBP6/YB-
1 interaction is localised within the C-terminal 62 amino acid region of YB-1 (Chibi et al., 
2008). That conclusion was based on the cDNA sequence of the yeast 2-hybrid prey isolated in 
the screen. The results of this study, although preliminary, suggest that the entire YB-1Y2H region 
may play a role in the interaction of RBBP6 with YB-1.  
 
All three interaction assays divided the YB-1Y2H region into approximately the same three 
fragments: YB-1261-291/CTD-1; YB-1277-306/CTD-2; YB-1292-324. The direct yeast 2-hybrid assay 
showed that both YB-1277-306 and YB-1292-324 interact with the RING finger domain of RBBP6, 
although the interaction with YB-1292-324 appeared to be much weaker than that with YB-1277-306. 
The assay could not be performed for YB-1261-291 because the attempt to make the Y2H construct 
was unsuccessful. The immunoprecipitation assay showed that YB-1292-324 is immunoprecipitated 
by RING. The assay could not be performed for YB-1277-306 because the attempt to generate this 
fragment in vitro was unsuccessful and for YB-1261-291 for the reason given above. The NMR 
chemical shift perturbation assay showed that both CTD-1 and CTD-2 interact with the RING 
finger domain of RBBP6 although the interaction with CTD-2 appeared to be weaker than that 
with CTD-1 (Fig. 3.11 and Fig. 3.13). Taken together, the results provide evidence that the 
interaction of YB-1261-291/CTD-1 is stronger than that of YB-1277-306/CTD-2 which is stronger 
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than that of YB-1292-324/CTD-3. However the conclusion is preliminary and would need further 
experimental investigation. 
 
5.2 Ubiquitination of YB-1 
The in vitro ubiquitination assay provides evidence that both UbcH5c and UbcH7 have E2 
activity against YB-1 in cooperation with RBBP6, but that Ubc13 does not (Fig. 4.1). Because of 
the promiscuity of UbcH5c it is perhaps not surprising that it supports RBBP6-mediated 
ubiquitination of YB-1. UbcH5c and Ubc13 both contain the S-P-A motif, which has been 
proposed to determine specificity for CHIP E3s (Xu et al., 2008). Since the RING finger domain 
of RBBP6 most closely resembles the U-box from CHIP (Pugh et al., unpublished data) we may 
therefore expect Ubc13 to also support RBBP6-mediated ubiquitination. Surprisingly it does not, 
but UbcH7, which does not contain the S-P-A motif, does. 
 
The observation that RBBP6 can interact with more than one E2 in YB-1 ubiquitination 
epitomizes functional redundancy within E2 enzyme family. Apart from RBBP6, there are some 
RING-containing E3s which have been shown to interact with more than one E2 enzyme. For 
example the breast cancer-associated E3, BRCA1 is known to interact with ten E2 enzymes  
(Christensen et al., 2009). The rationale behind the functional redundancy exhibited by E2 
enzymes is not clear. This is a surprising observation given that the E2 enzyme family has 
undergone evolutionary expansion (Markson et al., 2009). 
 
The method described in this study for the screening of E2s is quite robust and is not time 
consuming, implying that a set of E2s that interact with a given E3 enzyme can be defined within 
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a reasonable space of time. Also some E2 enzymes which evade detection by other methods are 
easily detected using this method. For example, biomolecular NMR failed to detect the 
interaction between UbcH5 and the RING finger domain of RBBP6 (Pugh and Klevitt 
unpublished data). However, it is noteworthy that the ubiquitination data shown in Fig. 4.1 is not 
fully convincing and hence additional studies will be required to fully substantiate the results. 
Additional studies may include a fully reconstituted assay using bacterially expressed YB-1 and 
HA-tagged ubiquitin, so that poly-ubiquitin chains can be detected by western-blotting with anti-
HA antibody.  
 
5.3 Implications of the RBBP6/YB-1 interaction for human health 
The findings of this study confirm that RBBP6 interacts with YB-1 at the same region as 
Heterogeneous Nuclear Ribonucleoprotein K (hnRNP K) and p53 (Fig. 5.1) (Sorokin et al., 
2007; Lasham et al., 2003; Zhang et al., 2005). Since RBBP6 is known to interact with p53, this 
may suggest that p53, YB-1 and RBBP6 are involved in a complex. The same applies to 
hnRNPK, which, like RBBP6, is involved in mRNA splicing. 
 
The RBBP6/YB-1 interaction has significant clinical implications as it presents a novel approach 
in the development of therapeutic strategies against cancer. The observation that RBBP6 
ubiquitinates YB-1, thereby marking it for destruction by the cell, implies that RBBP6 may 
repress YB-1-mediated cellular functions. The structural architecture of the RBBP6/YB-1 
interaction could therefore be used as a guide in the design of drugs to suppress levels of YB-1. 
Conceivably, the interaction between the RING finger domain of RBBP6 and YB-1 could be 
manipulated to produce a drug that mimics the RING finger in the manner in which it binds to 
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YB-1.  Such a drug may keep YB-1-mediated phenotypes at bay. Taken together, this implies 
that the RING finger domain of RBBP6 could be a disease-modifying and ‘druggable’ target. 
 
 
 
 
Fig. 5.1 An illustration of some of the proteins that interact with YB-1. The diagram shows the 
proteins known to interact with different regions of YB-1. Adapted from Sorokin et., al 2007. 
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5.4 Prospective studies 
Since the screening of E2s done in this study was done from a limited set of E2s, it is also 
possible that UbcH5 and UbcH7 are not the only E2s that interact with RBBP6. This therefore, 
provides the impetus for defining the whole set of RBBP6's cognate E2s. To accomplish this task 
a larger screen of E2s should be carried out. Since the findings of this study support the 
speculation that the RING finger domain of RBBP6 could be ‘druggable’ target, it is imperative 
to carry out NMR studies that investigate the druggability of this domain.  
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Appendix I: Amino acid sequence of CTDYB-1  
GGVPVQGSKYAADRNHYRRYPRRRGPPRNYQQNYQNSESGEKNEGSESAPEGQAQQR
RPYRRRRFPPYYMRRPYGRRPQYSNPPVQGEVMEGADNQGAGEQGRPVRQNMYRGYR
PRFRRGPPRQRQPREDGNEEDKENQGDETQGQQPPQRRYRRNFNYRRRRPENPKPQDG
KETKAADPPAENSSAPEAEQGGAE 
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Appendix II: Sequence analysis of YB-1277-306 cloned into pACT2 AD 
vector. 
Sequencing for pACT2-cloned inserts was done using the pACT2 forward primer.  
 
 
 Score =  193 bits (104),  Expect = 7e-55 
 Identities = 104/104 (100%), Gaps = 0/104 (0%) 
 Strand=Plus/Plus 
 
Query  1    GGATCCCTCAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACC  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCCTCAACGTCGGTACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACC  60 
 
Query  61   CTAAACCACAAGATGGCAAAGAGACAAAAGCAGCCTAACTCGAG  104 
            |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTAAACCACAAGATGGCAAAGAGACAAAAGCAGCCTAACTCGAG  104 
 
Restriction sites are highlighted in red  Xho I (CTCGAG)  and Bam HI (GGATCC). ‘Query’ 
denotes the expected sequence and ‘Sbjct’ denotes the experimental sequence determined for the 
sequence analysis of the cloned insert. The stop codon (TAA) is highlighted in yellow. 
 
 
Appendix III: Sequence analysis of YB-1292-324 cloned into pACT2 
AD vector. 
 
Score =  209 bits (113),  Expect = 8e-60 
Identities = 113/113 (100%), Gaps = 0/113 (0%) 
Strand=Plus/Plus 
 
Query  1    GGATCCCAGAAAACCCTAAACCACAAGATGGCAAAGAGACAAAAGCAGCCGATCCACCAG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCCAGAAAACCCTAAACCACAAGATGGCAAAGAGACAAAAGCAGCCGATCCACCAG  60 
 
Query  61   CTGAGAATTCGTCCGCTCCCGAGGCTGAGCAGGGCGGGGCTGAGTAACTCGAG  113 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTGAGAATTCGTCCGCTCCCGAGGCTGAGCAGGGCGGGGCTGAGTAACTCGAG  113 
 
Restriction sites are highlighted in red  Xho I (CTCGAG)  and Bam HI (GGATCC). ‘Query’ 
denotes the expected sequence and ‘Sbjct’ denotes the experimental sequence determined for the 
sequence analysis of the cloned insert. The stop codon (TAA) is highlighted in yellow. 
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Appendix IV: Sequence analysis of RING
N312D
 cloned into pGEX-6P-
2 vector. 
Score =  510 bits (276),  Expect = 1e-149 
 Identities = 278/279 (99%), Gaps = 0/279 (0%) 
 Strand=Plus/Plus 
 
Query  1    GGATCCGAAGATGATCCTATCCCAGATGAATTGTTGTGTCTCATCTGCAAGGATATTATG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCGAAGATGATCCTATCCCAGATGAATTGTTGTGTCTCATCTGCAAGGATATTATG  60 
 
Query  61   ACTGATGCTGTTGTGATTCCCTGCTGTGGAAACAGTTACTGTGATGAATGTATAAGAACA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   ACTGATGCTGTTGTGATTCCCTGCTGTGGAAACAGTTACTGTGATGAATGTATAAGAACA  120 
 
Query  121  GCACTCCTGGAATCAGATGAGCACACATGTCCGACGTGTCATCAAAATGATGTTTCTCCT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GCACTCCTGGAATCAGATGAGCACACATGTCCGACGTGTCATCAAAATGATGTTTCTCCT  180 
 
Query  181  GATGCTTTAATTGCCAATAAATTTTTACGACAGGCTGTAAATAACTTCAAAAATGAAACT  240 
            ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  GATGCTTTAATTGCCGATAAATTTTTACGACAGGCTGTAAATAACTTCAAAAATGAAACT  240 
 
Query  241  GGCTATACAAAAAGACTACGAAAACAGTGATAACTCGAG  279 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GGCTATACAAAAAGACTACGAAAACAGTGATAACTCGAG  279 
 
 
The query represents the wildtype sequence and the subject (Sbjct) represents the mutant 
sequence. The mutated codon is shown in green. AAT codon in the wildtype codes for 
Asperagine, N and the substitution mutation GAT in the mutant codes for Aspartic acid, D. 
Restriction sites are highlighted in red Xho I (CTCGAG) and Bam HI (GGATCC). ‘Query’ 
denotes the expected sequence and ‘Sbjct’ denotes the experimental sequence determined for the 
sequence analysis of the cloned insert. The stop codons (TAA and TGA) are highlighted in 
yellow. 
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Appendix V: Sequence analysis of RING
K313E
 cloned into pGEX-6P-
2 vector. 
Score =  505 bits (273),  Expect = 6e-148 
 Identities = 277/279 (99%), Gaps = 0/279 (0%) 
 Strand=Plus/Plus 
 
Query  1    GGATCCGAAGATGATCCTATCCCAGATGAATTGTTGTGTCTCATCTGCAAGGATATTATG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGATCCGAAGATGATCCTATCCCAGATGAATTGTTGTGTCTCATCTGCAAGGATATTATG  60 
 
Query  61   ACTGATGCTGTTGTGATTCCCTGCTGTGGAAACAGTTACTGTGATGAATGTATAAGAACA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   ACTGATGCTGTTGTGATTCCCTGCTGTGGAAACAGTTACTGTGATGAATGTATAAGAACA  120 
 
Query  121  GCACTCCTGGAATCAGATGAGCACACATGTCCGACGTGTCATCAAAATGATGTTTCTCCT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GCACTCCTGGAATCAGATGAGCACACATGTCCGACGTGTCATCAAAATGATGTTTCTCCT  180 
 
Query  181  GATGCTTTAATTGCCAATAAATTTTTACGACAGGCTGTAAATAACTTCAAAAATGAAACT  240 
            |||||||||||||||||| |||||||||||||||| |||||||||||||||||||||||| 
Sbjct  181  GATGCTTTAATTGCCAATGAATTTTTACGACAGGCCGTAAATAACTTCAAAAATGAAACT  240 
 
Query  241  GGCTATACAAAAAGACTACGAAAACAGTGATAACTCGAG  279 
            ||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GGCTATACAAAAAGACTACGAAAACAGTGATAACTCGAG  279 
 
The query represents the wildtype sequence and the subject (Sbjct) represents the mutant 
sequence. The mutated codon is shown in green. AAA codon in the wildtype codes for Lysine, K 
and the substitution mutation GAA in the mutant codes for Glutamic acid, D. Restriction sites 
are highlighted in red Xho I (CTCGAG) and Bam HI (GGATCC). ‘Query’ denotes the expected 
sequence and ‘Sbjct’ denotes the experimental sequence determined for the sequence analysis of 
the cloned insert. The stop codons (TAA and TGA) are highlighted in yellow. 
 
 
 
 
 
